Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination...
Saved in:
| Published in | Journal for immunotherapy of cancer Vol. 10; no. 5; p. e003956 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BMJ Publishing Group Ltd
01.05.2022
BMJ Publishing Group LTD BMJ Publishing Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2051-1426 2051-1426 |
| DOI | 10.1136/jitc-2021-003956 |
Cover
| Abstract | Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination with other ICIs or chemotherapy—have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC’s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma. |
|---|---|
| AbstractList | Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination with other ICIs or chemotherapy—have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC’s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma. Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)- either as monotherapy or in combination with other ICIs or chemotherapy-have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small-cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC's 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma.Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)- either as monotherapy or in combination with other ICIs or chemotherapy-have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small-cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC's 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma. |
| Author | Forde, Patrick M Neal, Joel W Sagorsky, Sarah Sepesi, Boris Davies, Marianne Hassan, Raffit Schwartz, Lawrence H Govindan, Ramaswamy Morgensztern, Daniel Antonia, Scott J Hellmann, Matthew D Aggarwal, Charu Dubinett, Steven M Malik, Shakun Rimm, David L Hirsch, Fred R Patel, Jyoti D Garon, Edward B Goldberg, Sarah B Herbst, Roy S Ferris, Andrea Johnson, Melissa L |
| AuthorAffiliation | 3 Division of Medical Oncology, Department of Medicine , Duke Cancer Institute Center for Cancer Immunotherapy , Durham , North Carolina , USA 4 Yale School of Nursing , Yale Cancer Center , New Haven , Connecticut , USA 10 Thoracic and GI Malignancies Branch , National Cancer Institute , Bethesda , Maryland , USA 8 Division of Hematology/Oncology, Department of Medicine , University of California Los Angeles David Geffen School of Medicine , Los Angeles , California , USA 19 Department of Radiology, Vagelos College of Physicians and Surgeons , Columbia University Medical Center , New York , New York , USA 9 Section of Medical Oncology , Yale University School of Medicine, Yale Cancer Center , New Haven , Connecticut , USA 17 Robert H. Lurie Comprehensive Cancer Center , Northwestern University , Evanston , Illinois , USA 18 Department of Pathology , Yale University School of Medicine , New Haven , Connecticut , USA 20 Department of Thoracic and Cardiovascular Surgery, Division of Surgery , Un |
| AuthorAffiliation_xml | – name: 8 Division of Hematology/Oncology, Department of Medicine , University of California Los Angeles David Geffen School of Medicine , Los Angeles , California , USA – name: 18 Department of Pathology , Yale University School of Medicine , New Haven , Connecticut , USA – name: 3 Division of Medical Oncology, Department of Medicine , Duke Cancer Institute Center for Cancer Immunotherapy , Durham , North Carolina , USA – name: 16 Stanford Cancer Institute , Stanford University , Stanford , California , USA – name: 2 Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center , University of Pennsylvania , Philadelphia , Pennsylvania , USA – name: 13 Sarah Cannon Research Institute , Nashville , Tennessee , USA – name: 11 Memorial Sloan Kettering Cancer Center , New York , New York , USA – name: 5 Division of Pulmonary and Critical Care Medicine, Department of Medicine , University of California Los Angeles David Geffen School of Medicine , Los Angeles , California , USA – name: 17 Robert H. Lurie Comprehensive Cancer Center , Northwestern University , Evanston , Illinois , USA – name: 7 Upper Aerodigestive Division, Department of Oncology , Johns Hopkins University School of Medicine , Baltimore , Maryland , USA – name: 10 Thoracic and GI Malignancies Branch , National Cancer Institute , Bethesda , Maryland , USA – name: 15 Division of Cancer Treatment & Diagnosis, CTEP , National Cancer Institute , Rockville , Maryland , USA – name: 20 Department of Thoracic and Cardiovascular Surgery, Division of Surgery , University of Texas MD Anderson Cancer Center , Houston , Texas , USA – name: 9 Section of Medical Oncology , Yale University School of Medicine, Yale Cancer Center , New Haven , Connecticut , USA – name: 19 Department of Radiology, Vagelos College of Physicians and Surgeons , Columbia University Medical Center , New York , New York , USA – name: 4 Yale School of Nursing , Yale Cancer Center , New Haven , Connecticut , USA – name: 12 Center for Thoracic Oncology , Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai , New York , New York , USA – name: 6 LUNGevity Foundation , Chicago , Illinois , USA – name: 14 Tennessee Oncology/One Oncology , Nashville , Tennessee , USA – name: 1 Department of Medicine, Oncology Division, Medical Oncology , Washington University School of Medicine in Saint Louis , St Louis , Missouri , USA |
| Author_xml | – sequence: 1 givenname: Ramaswamy surname: Govindan fullname: Govindan, Ramaswamy organization: Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA – sequence: 2 givenname: Charu surname: Aggarwal fullname: Aggarwal, Charu organization: Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA – sequence: 3 givenname: Scott J surname: Antonia fullname: Antonia, Scott J organization: Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Cancer Immunotherapy, Durham, North Carolina, USA – sequence: 4 givenname: Marianne surname: Davies fullname: Davies, Marianne organization: Yale School of Nursing, Yale Cancer Center, New Haven, Connecticut, USA – sequence: 5 givenname: Steven M surname: Dubinett fullname: Dubinett, Steven M organization: Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA – sequence: 6 givenname: Andrea surname: Ferris fullname: Ferris, Andrea organization: LUNGevity Foundation, Chicago, Illinois, USA – sequence: 7 givenname: Patrick M surname: Forde fullname: Forde, Patrick M organization: Upper Aerodigestive Division, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA – sequence: 8 givenname: Edward B orcidid: 0000-0001-7077-8801 surname: Garon fullname: Garon, Edward B organization: Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA – sequence: 9 givenname: Sarah B surname: Goldberg fullname: Goldberg, Sarah B organization: Section of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA – sequence: 10 givenname: Raffit surname: Hassan fullname: Hassan, Raffit organization: Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA – sequence: 11 givenname: Matthew D orcidid: 0000-0002-2670-9777 surname: Hellmann fullname: Hellmann, Matthew D organization: Memorial Sloan Kettering Cancer Center, New York, New York, USA – sequence: 12 givenname: Fred R surname: Hirsch fullname: Hirsch, Fred R organization: Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, New York, USA – sequence: 13 givenname: Melissa L surname: Johnson fullname: Johnson, Melissa L organization: Tennessee Oncology/One Oncology, Nashville, Tennessee, USA – sequence: 14 givenname: Shakun surname: Malik fullname: Malik, Shakun organization: Division of Cancer Treatment & Diagnosis, CTEP, National Cancer Institute, Rockville, Maryland, USA – sequence: 15 givenname: Daniel surname: Morgensztern fullname: Morgensztern, Daniel organization: Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA – sequence: 16 givenname: Joel W surname: Neal fullname: Neal, Joel W organization: Stanford Cancer Institute, Stanford University, Stanford, California, USA – sequence: 17 givenname: Jyoti D surname: Patel fullname: Patel, Jyoti D organization: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USA – sequence: 18 givenname: David L orcidid: 0000-0001-5820-4397 surname: Rimm fullname: Rimm, David L organization: Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA – sequence: 19 givenname: Sarah surname: Sagorsky fullname: Sagorsky, Sarah organization: Upper Aerodigestive Division, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA – sequence: 20 givenname: Lawrence H surname: Schwartz fullname: Schwartz, Lawrence H organization: Department of Radiology, Vagelos College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, USA – sequence: 21 givenname: Boris surname: Sepesi fullname: Sepesi, Boris organization: Department of Thoracic and Cardiovascular Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 22 givenname: Roy S surname: Herbst fullname: Herbst, Roy S email: roy.herbst@yale.edu organization: Section of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35640927$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk9v1DAQxSNUREvpnROyxKWVCPhPYieXSmhVYKVKHFrO1sQZb71K7MVJkPYj8K1xSCndSiAfbI3f-2nGfi-zIx88ZtlrRt8zJuSHrRtNzilnOaWiLuWz7ITTkuWs4PLo0fk4OxuGLaWUUSGqqnqRHYtSFrTm6iT7eROMw3FPbIhk3feTD-MdRtjtSbBkBd5gJOc369vVBTGd885AR3YRzOgMks3kWkxVJMETd-CeeelMxogw9ujHmddNfkPMAgXfkh6H2dC50MOr7LmFbsCz-_00-_bp6nb1Jb_--nm9-nidNyVXY95YibJliA1w3qJpleFNXbeSWQklCFZVjZCAtqpYzWxrayGkQkWhKBRaJk6z9cJtA2z1Lroe4l4HcPp3IcSNhpim61CDogWzVjUNU4VBgGSvC0AmeMuM4Il1ubB2U9Nja9KYEboD6OGNd3d6E37ompVKCJUA5_eAGL5POIy6d4PBrgOPYRo0l4qLeZVJ-vaJdBum6NNTzaqiEikKdVK9edzRQyt_fjwJ6CIwMQxDRPsgYVTPudJzrvScK73kKlnkE4txI4wuzDO57n_Gd4ux6bd_u_2n_BeYy-LP |
| CitedBy_id | crossref_primary_10_1038_s41698_024_00704_9 crossref_primary_10_3389_fonc_2023_1216999 crossref_primary_10_1002_1878_0261_13474 crossref_primary_10_3389_fimmu_2023_1125111 crossref_primary_10_3390_curroncol30090628 crossref_primary_10_1016_j_bulcan_2024_08_017 crossref_primary_10_1002_cam4_6645 crossref_primary_10_1080_2162402X_2024_2377830 crossref_primary_10_1186_s12885_023_11203_8 crossref_primary_10_1136_jitc_2023_006913 crossref_primary_10_3389_fimmu_2025_1537520 crossref_primary_10_1007_s00228_024_03789_0 crossref_primary_10_1186_s12931_023_02321_9 crossref_primary_10_1016_j_cllc_2023_01_013 crossref_primary_10_1016_j_ejca_2023_113457 crossref_primary_10_1007_s10238_023_00999_1 crossref_primary_10_1038_s41591_024_02808_y crossref_primary_10_1371_journal_pone_0299760 crossref_primary_10_3390_cancers14246250 |
| Cites_doi | 10.1016/j.jtho.2023.03.008 10.1016/S0140-6736(21)02098-5 10.1038/s41571-021-00473-5 10.1093/jnci/92.3.205 10.1016/j.soncn.2019.08.012 10.1056/NEJMoa1801946 10.1016/j.jss.2015.01.043 10.1001/jamaoncol.2018.3676 10.1038/s41416-020-01099-7 10.1016/S1470-2045(16)30098-5 10.1093/annonc/mdy275 10.1056/NEJMoa1809697 10.1200/JCO.21.00174 10.1056/NEJMoa2307980 10.1056/NEJMoa1606774 10.1016/S1470-2045(17)30690-3 10.1001/jamaoncol.2017.3808 10.1371/journal.pone.0229179 10.1016/S0140-6736(20)32714-8 10.1188/14.CJON.637-640 10.1002/pon.3055 10.1002/cncr.32692 10.21037/tlcr-23-115 10.1200/JCO.2020.38.15_suppl.9001 10.1200/JCO.2017.77.6385 10.1200/JOP.2014.001542 10.1097/COC.0000000000000239 10.6004/jnccn.2018.0047 10.1016/S0959-8049(05)80262-X 10.1200/JCO.19.00189 10.1200/JCO.1993.11.3.570 10.1038/bjc.2013.585 10.1200/JCO.2017.76.7293 10.1016/j.jtho.2019.08.424 10.1002/pon.5025 10.15585/mmwr.mm6608a3 10.21037/tlcr.2019.05.01 10.1200/JCO.2017.77.0305 10.1200/JCO.2021.39.15_suppl.8503 10.1054/bjoc.2000.1164 10.1016/S2213-2600(19)30084-0 10.1016/j.ejca.2008.10.026 10.1056/NEJMoa2404873 10.1016/j.annonc.2021.09.016 10.1073/pnas.0712237105 10.1016/j.jtho.2016.11.2228 10.1016/j.ctrv.2017.07.002 10.1093/annonc/mdy041 10.1186/1479-5876-10-179 10.1093/annonc/mdz264 10.1016/j.jtho.2019.12.109 10.1016/j.ajhg.2013.04.012 10.1007/s00262-008-0642-y 10.1158/2159-8290.CD-17-0593 10.1016/j.critrevonc.2014.11.005 10.1016/j.lungcan.2013.03.008 10.6004/jnccn.2018.0062 10.18632/oncotarget.21567 10.1016/S1470-2045(19)30167-6 10.1146/annurev.iy.12.040194.002005 10.1002/j.1460-2075.1992.tb05481.x 10.1016/S1470-2045(20)30539-8 10.1001/jamanetworkopen.2019.2535 10.1016/j.jtho.2021.07.009 10.1016/S1470-2045(17)30074-8 10.6004/jnccn.2019.7310 10.2147/OTT.S100685 10.1200/JCO.2016.34.15_suppl.3025 10.1056/NEJMoa1716948 10.1016/j.jtho.2018.04.039 10.1016/j.annonc.2022.01.074 10.1016/j.jtho.2018.11.016 10.1053/j.seminoncol.2004.04.008 10.1016/S0140-6736(15)01281-7 10.1056/NEJMoa2304875 10.1016/j.jtho.2018.08.2035 10.1093/annonc/mdz167 10.1007/s11523-020-00745-7 10.1200/JCO.20.00793 10.1016/S0140-6736(23)01613-6 10.1016/S1470-2045(17)30230-9 10.1038/s41467-018-08170-1 10.1016/j.cllc.2024.03.003 10.3389/fonc.2021.739090 10.1016/S1470-2045(18)30139-6 10.1056/NEJMoa1716078 10.1016/j.ejca.2016.03.081 10.1093/annonc/mdy554 10.1200/JCO.2016.68.2005 10.1016/j.cllc.2016.12.010 10.1038/modpathol.2015.65 10.1186/s40425-019-0585-1 10.1016/S1470-2045(22)00518-6 10.1200/JCO.19.02446 10.3747/co.v16i2.376 10.1200/JCO.20.02212 10.1158/1538-7445.AM2021-CT003 10.1016/j.jtho.2018.05.013 10.20517/2394-4722.2019.38 10.1056/NEJMoa2311926 10.1200/JCO.2008.17.7162 10.1634/theoncologist.2017-0078 10.1016/j.cllc.2018.05.011 10.1016/S0140-6736(18)32409-7 10.1016/S0140-6736(19)32222-6 10.1056/NEJMoa1809064 10.1016/j.annonc.2020.03.287 10.1097/JTO.0000000000000244 10.1186/s40425-017-0300-z 10.1016/j.jad.2012.03.025 10.1001/jamaoncol.2017.4526 10.1056/NEJMoa1910231 10.1200/JCO.2016.66.8459 10.1016/j.jtho.2018.04.010 10.1093/annonc/mdz063 10.3322/caac.21492 10.1200/JCO.2015.61.6870 10.1038/ni1443 10.1200/JCO.18.00149 10.1200/JCO.2021.39.15_suppl.9001 10.1056/NEJM199212033272302 10.3390/ijms20092194 10.1200/JCO.2017.75.1644 10.1038/s41379-019-0349-y 10.1038/ncponc1183 10.1016/j.cell.2015.03.030 10.1200/PO.17.00073 10.1136/jitc-2019-000398 10.1136/thx.2004.031872 10.1056/NEJMoa1917346 10.3322/caac.21708 10.1016/j.jtho.2020.06.015 10.1158/1078-0432.CCR-09-1624 10.1200/JCO.20.01605 10.1016/j.resinv.2019.05.002 10.1016/j.jtho.2018.04.034 10.1016/j.jtho.2018.11.028 10.1158/1078-0432.CCR-13-0895 10.1016/S0140-6736(21)00228-2 10.1016/j.jtho.2019.10.002 10.1056/NEJMoa2302983 10.1200/JCO.2003.11.136 10.1016/0169-5002(95)00450-F 10.1016/j.cllc.2017.02.008 10.1007/s40265-022-01827-8 10.1001/jamaoncol.2016.2453 10.1634/theoncologist.2012-0279 10.1056/NEJMc1614298 10.1016/j.cllc.2019.10.009 10.1016/j.lungcan.2014.08.017 10.1093/neuonc/now235 10.1016/j.cllc.2019.02.018 10.1200/JCO.2020.38.15_suppl.9501 10.1016/S1470-2045(20)30641-0 10.1016/j.prro.2020.02.009 10.1038/s41591-021-01541-0 10.1186/s40425-018-0382-2 10.1200/JCO.19.03136 10.1200/JCO.2017.74.3062 10.1016/j.immuni.2013.07.012 10.1038/s41591-020-01224-2 10.1634/theoncologist.2015-0498 10.1186/s40425-019-0645-6 10.1001/jamaoncol.2017.0013 10.1016/S0140-6736(15)01238-6 10.1136/jitc-2021-002435 10.1084/jem.182.2.459 10.1016/j.annonc.2021.01.071 10.1007/s12253-018-0469-6 10.1155/2017/1310478 10.1200/JCO.2021.39.15_suppl.9016 10.1200/JCO.1998.16.1.145 10.2147/CMAR.S52543 10.1158/1078-0432.CCR-19-0624 10.1200/JCO.2020.38.15_suppl.9000 10.1016/s1470-2045(17)30690-3 10.1016/s0140-6736(20)32714-8 10.17226/13058 10.1158/1538-7445.AM2020-CT221 |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2025 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2022 |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2025 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2022 |
| DBID | 9YT ACMMV AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1136/jitc-2021-003956 |
| DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: ACMMV name: BMJ Journals:Open Access url: https://journals.bmj.com/ sourceTypes: Publisher – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2051-1426 |
| ExternalDocumentID | oai_doaj_org_article_a7041ff7bb174ceaaf1394ae132d1c32 PMC9157337 35640927 10_1136_jitc_2021_003956 jitc |
| Genre | Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GroupedDBID | 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV ADRAZ AFKRA AHBYD AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBS FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR KQ8 M1P M48 M~E OK1 PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO RBZ RMJ RPM RSV SOJ UKHRP AAYXX ADUKV AHSBF CITATION EJD H13 ITC ROL CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-b527t-bf6e6d1eeba22decd7c2b99d61f6a5a3188b36aef88191fdf93367e70a447ef13 |
| IEDL.DBID | M48 |
| ISSN | 2051-1426 |
| IngestDate | Wed Aug 27 01:29:36 EDT 2025 Thu Aug 21 14:14:19 EDT 2025 Fri Sep 05 13:07:18 EDT 2025 Fri Jul 25 08:51:32 EDT 2025 Wed Jul 23 01:46:01 EDT 2025 Thu Apr 24 23:08:15 EDT 2025 Thu Aug 07 06:39:04 EDT 2025 Wed Jul 30 14:20:19 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | clinical trials as topic lung neoplasms guidelines as topic immunotherapy |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b527t-bf6e6d1eeba22decd7c2b99d61f6a5a3188b36aef88191fdf93367e70a447ef13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-5820-4397 0000-0001-7077-8801 0000-0002-2670-9777 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1136/jitc-2021-003956 |
| PMID | 35640927 |
| PQID | 2674832029 |
| PQPubID | 2040222 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a7041ff7bb174ceaaf1394ae132d1c32 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9157337 proquest_miscellaneous_2672323235 proquest_journals_2674832029 pubmed_primary_35640927 crossref_primary_10_1136_jitc_2021_003956 crossref_citationtrail_10_1136_jitc_2021_003956 bmj_journals_10_1136_jitc_2021_003956 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-05-01 |
| PublicationDateYYYYMMDD | 2022-05-01 |
| PublicationDate_xml | – month: 05 year: 2022 text: 2022-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
| PublicationTitle | Journal for immunotherapy of cancer |
| PublicationTitleAbbrev | J Immunother Cancer |
| PublicationTitleAlternate | J Immunother Cancer |
| PublicationYear | 2022 |
| Publisher | BMJ Publishing Group Ltd BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BMJ Publishing Group Ltd – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | Vogelzang, Rusthoven, Symanowski (R122) 2003; 21 Ishida, Agata, Shibahara (R25) 1992; 11 Shankar, Abedalthagafi, Vaubel (R120) 2017; 19 Mazurek, Syamlal, Wood (R112) 2017; 66 Reck, Rodríguez-Abreu, Robinson (R68) 2019; 37 Linden, Vodermaier, Mackenzie (R169) 2012; 141 Mansfield, Symanowski, Peikert (R116) 2014; 86 Cella, Bonomi, Lloyd (R185) 1995; 12 TSK, Wu, Kudaba (R192) 2019; 30 Baas, Scherpereel, Nowak (R14) 2021; 397 Kalemkerian, Narula, Kennedy (R57) 2018; 36 Eisenhauer, Therasse, Bogaerts (R128) 2009; 45 Elliott, Bai, Hsieh (R59) 2020; 15 Morrison, Novotny, Sloan (R173) 2017; 18 West, McCleod, Hussein (R6) 2019; 20 Paz-Ares, Vicente, Tafreshi (R76) 2020; 15 Ahn, Cho, Felip (R106) 2023; 389 Barlesi, Audigier-Valette, Felip (R150) 2019; 14 Sharma, Allison (R23) 2015; 161 Sul, Blumenthal, Jiang (R73) 2016; 21 Pulford, Huilgol, Moffat (R118) 2017; 2017 Krummel, Allison (R22) 1995; 182 Cheng, Spigel, Cho (R100) 2024; 391 Goldman, Dvorkin, Chen (R102) 2021; 22 Gralla, Hollen, Msaouel (R166) 2014; 9 Socinski, Nishio, Jotte (R78) 2021; 16 Forde, Anagnostou, Sun (R126) 2021; 27 Therasse, Arbuck, Eisenhauer (R127) 2000; 92 Spigel, Vicente, Ciuleanu (R108) 2021; 32 Curran, Sahmoud, Therasse (R114) 1998; 16 Sullivan, Forsberg, Ganzini (R177) 2016; 34 Tsao, Kerr, Kockx (R45) 2018; 13 Brahmer, Rodríguez-Abreu, Robinson (R189) 2017; 18 Gray, Villegas, Daniel (R4) 2020; 15 Sharp, Carsin, Timmons (R179) 2013; 22 Wu, Planchard, Lu (R56) 2019; 30 Leal, Wang, Dowlati (R104) 2020; 38 Baas, Scherpereel, Nowak (R124) 2021; 397 Reck, Ciuleanu, Dols (R28) 2020; 38 Gettinger, Choi, Hastings (R33) 2017; 7 Paz-Ares, Dvorkin, Chen (R101) 2019; 394 Horn, Spigel, Vokes (R10) 2017; 35 Armato, Nowak (R139) 2018; 13 Brahmer, Lacchetti, Schneider (R154) 2018; 36 Katz, Hammer, Bagley (R140) 2018; 13 Cella (R186) 2004; 31 Popova, Hebert, Jacquemin (R121) 2013; 92 Sezer, Kilickap, Gümüş (R11) 2021; 397 Evans, O'Sullivan, Hughes (R38) 2020; 26 Ferrara, Mezquita, Texier (R142) 2018; 4 O’Brien, Paz-Ares, Marreaud (R17) 2022; 23 Sung, Patel, Djalalov (R168) 2017; 18 Brahmer, Govindan, Anders (R191) 2018; 6 Suresh, Psoter, Voong (R159) 2019; 14 Valenti (R163) 2014; 18 Wakelee, Liberman, Kato (R16) 2023; 389 Hwang, Niemierko, Hwang (R70) 2018; 4 Forde, Chaft, Smith (R143) 2018; 378 Hirsch, McElhinny, Stanforth (R47) 2017; 12 Iyer, Taylor-Stokes, Roughley (R167) 2013; 81 Socinski, Jotte, Cappuzzo (R77) 2018; 378 Salvo, Hadi, Napolskikh (R171) 2009; 16 Bray, Ferlay, Soerjomataram (R1) 2018; 68 Buchbinder, Desai (R31) 2016; 39 Keam (R32) 2023; 83 Webster, O'Connor, Hansen (R187) 2020; 6 Forde, Spicer, Lu (R89) 2021; 81 Reck, Liu, Mansfield (R13) 2019; 30 Reck, Mok, Nishio (R26) 2019; 7 Zafar, McNeil, Thomas (R178) 2015; 11 Herbst, Giaccone, de Marinis (R41) 2020; 383 Ledezma, Heng (R165) 2013; 6 Suresh, Voong, Shankar (R158) 2018; 13 Antonia, Villegas, Daniel (R86) 2018; 379 Long, Atkinson, Lo (R99) 2018; 19 Thompson (R153) 2018; 16 Pujol, Carestia, Daurès (R93) 2000; 83 Bonneville, Krook, Kautto (R49) 2017; 2017 Paz-Ares, Ciuleanu, Cobo (R12) 2021; 22 Rudin, Awad, Navarro (R103) 2020; 38 Seymour, Bogaerts, Perrone (R136) 2017; 18 Leonardi, Gainor, Altan (R145) 2018; 36 Polanski, Jankowska-Polanska, Rosinczuk (R175) 2016; 9 Cella, Tulsky, Gray (R183) 1993; 11 Chu, Perrone, Greillier (R18) 2023; 402 Doroshow, Bhalla, Beasley (R39) 2021; 18 Oshima, Tanimoto, Yuji (R65) 2018; 4 Vega, Yee, McShane (R52) 2021; 32 Sharpe, Wherry, Ahmed (R24) 2007; 8 Voong, Hazell, Fu (R97) 2019; 20 Nishino, Giobbie-Hurder, Hatabu (R161) 2016; 2 Cascone, William, Weissferdt (R141) 2021; 27 Win, Sharples, Wells (R170) 2005; 60 Tang, Kang (R105) 2023; 12 Boon, Cerottini, Van den Eynde (R20) 1994; 12 Chiou, Burotto (R130) 2015; 33 Ettinger, Aisner, Wood (R55) 2018; 16 Hollen, Gralla, Kris (R184) 1993; 29A Suppl 1 Yang, Gadgeel, Sequist (R62) 2019; 14 Kim, Kwon, Park (R48) 2017; 8 Nesbit, Leal, Kruser (R96) 2019; 8 Carbone, Ferris, Baumann (R119) 2012; 10 Johnson, Cho, Luft (R15) 2023; 41 Midha, Sharpe, Scott (R53) 2016; 34 Nishino, Giobbie-Hurder, Gargano (R138) 2013; 19 Queirolo, Spagnolo (R131) 2017; 59 Lai, Lin, Hwang (R148) 2019; 20 Gadgeel, Rodríguez-Abreu, Speranza (R9) 2020; 38 Zalcman, Mazieres, Margery (R123) 2016; 387 Herbst, Baas, Kim (R7) 2016; 387 Wolchok, Hoos, O'Day (R135) 2009; 15 Vokes, Ready, Felip (R81) 2018; 29 Spicer, Wang, Tanaka (R90) 2021; 39 Couey, Bell, Patel (R156) 2019; 7 Paz-Ares, Ciuleanu, Lee (R5) 2021; 39 Leung, Laskin, Wu (R174) 2019; 28 Planchard, Popat, Kerr (R54) 2018; 29 Pignon, Arriagada, Ihde (R94) 1992; 327 Lasa-Blandon, Stasi, Hehir (R164) 2019; 35 Reck, Rodríguez-Abreu, Robinson (R67) 2016; 375 Hodi, Butler, Oble (R133) 2008; 105 Haslam, Prasad (R36) 2019; 2 Mazieres, Drilon, Lusque (R61) 2019; 30 Cigognetti, Lonardi, Fisogni (R117) 2015; 28 Rimm, Han, Taube (R46) 2017; 3 Mok, Wu, Kudaba (R8) 2019; 393 Di Giacomo, Danielli, Guidoboni (R132) 2009; 58 Meyerhoff, Yang, Speicher (R115) 2015; 196 Naidoo, Wang, Woo (R157) 2017; 35 Haspinger, Agustoni, Torri (R58) 2015; 94 Hellmann, Ciuleanu, Pluzanski (R51) 2018; 378 Felip, Altorki, Zhou (R88) 2021; 398 Herbst, Garon, Kim (R74) 2020; 38 Horn, Mansfield, Szczęsna (R193) 2018; 379 Borghaei, Gettinger, Vokes (R82) 2021; 39 Hodi, Oble, Drappatz (R134) 2008; 5 Barnett, Barta, Jhaveri (R146) 2017; 376 Abdel-Wahab, Safa, Abudayyeh (R147) 2019; 7 Hansen, Ala-Leppilampi, McKillop (R188) 2020; 126 Borghaei, Pluzanski, Caro (R72) 2020; 80 Owonikoko, Park, Govindan (R109) 2021; 39 Reck, Rodríguez-Abreu, Robinson (R69) 2021; 39 Zaorsky, Zhang, Tuanquin (R176) 2019; 10 Bordoni, Ciardiello, von Pawel (R190) 2018; 19 Akinboro, Vallejo, Mishra-Kalyani (R71) 2021; 39 Simone, Bogart, Cabrera (R95) 2020; 10 Chen, Mellman (R21) 2013; 39 Hodi, Ballinger, Lyons (R137) 2018; 36 Hellmann, Paz-Ares, Bernabe Caro (R42) 2019; 381 Garon, Cho, Luft (R85) 2024; 25 Brahmer, Abu-Sbeih, Ascierto (R152) 2021; 9 Antonia, López-Martin, Bendell (R107) 2016; 17 Peters, Scherpereel, Cornelissen (R125) 2022 Nakanishi, Masuda, Yamaguchi (R162) 2019; 57 Suresh, Naidoo (R160) 2020; 21 Rudin, Awad, Navarro (R27) 2020; 38 Makharadze, Gogishvili, Melkadze (R83) 2023; 18 Vuong, Nguyen, Nguyen (R60) 2020; 15 Creelan, Yeh, Kim (R63) 2021; 124 Widmaier, Wiestler, Walker (R43) 2020; 33 Chung, Piha-Paul, Lopez-Martin (R110) 2020; 15 Wintner, Giesinger, Zabernigg (R172) 2013; 109 Kluger, Tawbi, Ascierto (R34) 2020; 8 Paz-Ares, Spira, Raben (R87) 2020; 31 Siegel, Miller, Fuchs (R2) 2022; 72 Heymach, Harpole, Mitsudomi (R91) 2023; 389 Pai-Scherf, Blumenthal, Li (R75) 2017; 22 Leighl, Page, Raymond (R50) 2019; 25 Tian, Yu, Li (R64) 2021; 11 Zafar, Peppercorn, Schrag (R180) 2013; 18 Ricciuti, Dahlberg, Adeni (R149) 2019; 37 (R66) 2008; 26 Cascone, Awad, Spicer (R92) 2024; 390 Fehrenbacher, von Pawel, Park (R80) 2018; 13 Puzanov, Diab, Abdallah (R151) 2017; 5 Schwartz, Litière, de Vries (R129) 2016; 62 Takahashi, Yamanaka, Seto (R98) 2017; 18 Kennedy, Bhatia, Thompson (R144) 2019; 17 Leal (2025072923350935000_10.5.e003956.104) 2020; 38 Wintner (2025072923350935000_10.5.e003956.172) 2013; 109 Cella (2025072923350935000_10.5.e003956.186) 2004; 31 Hodi (2025072923350935000_10.5.e003956.134) 2008; 5 Schwartz (2025072923350935000_10.5.e003956.129) 2016; 62 Seymour (2025072923350935000_10.5.e003956.136) 2017; 18 Voong (2025072923350935000_10.5.e003956.97) 2019; 20 Zafar (2025072923350935000_10.5.e003956.178) 2015; 11 Valenti (2025072923350935000_10.5.e003956.163) 2014; 18 2025072923350935000_10.5.e003956.193 2025072923350935000_10.5.e003956.190 2025072923350935000_10.5.e003956.191 Ricciuti (2025072923350935000_10.5.e003956.149) 2019; 37 Akinboro (2025072923350935000_10.5.e003956.71) 2021; 39 Kalemkerian (2025072923350935000_10.5.e003956.57) 2018; 36 2025072923350935000_10.5.e003956.183 2025072923350935000_10.5.e003956.181 2025072923350935000_10.5.e003956.182 2025072923350935000_10.5.e003956.180 Haslam (2025072923350935000_10.5.e003956.36) 2019; 2 Herbst (2025072923350935000_10.5.e003956.41) 2020; 383 Webster (2025072923350935000_10.5.e003956.187) 2020; 6 Garon (2025072923350935000_10.5.e003956.85) 2024; 25 2025072923350935000_10.5.e003956.189 Barnett (2025072923350935000_10.5.e003956.146) 2017; 376 2025072923350935000_10.5.e003956.185 2025072923350935000_10.5.e003956.171 TSK (2025072923350935000_10.5.e003956.192) 2019; 30 2025072923350935000_10.5.e003956.91 2025072923350935000_10.5.e003956.92 2025072923350935000_10.5.e003956.95 2025072923350935000_10.5.e003956.96 Abdel-Wahab (2025072923350935000_10.5.e003956.147) 2019; 7 2025072923350935000_10.5.e003956.93 2025072923350935000_10.5.e003956.94 2025072923350935000_10.5.e003956.179 2025072923350935000_10.5.e003956.99 Morrison (2025072923350935000_10.5.e003956.173) 2017; 18 2025072923350935000_10.5.e003956.176 2025072923350935000_10.5.e003956.177 2025072923350935000_10.5.e003956.175 2025072923350935000_10.5.e003956.79 Paz-Ares (2025072923350935000_10.5.e003956.87) 2020; 31 Reck (2025072923350935000_10.5.e003956.13) 2019; 30 2025072923350935000_10.5.e003956.80 Puzanov (2025072923350935000_10.5.e003956.151) 2017; 5 Doroshow (2025072923350935000_10.5.e003956.39) 2021; 18 2025072923350935000_10.5.e003956.84 2025072923350935000_10.5.e003956.82 Tian (2025072923350935000_10.5.e003956.64) 2021; 11 2025072923350935000_10.5.e003956.88 Suresh (2025072923350935000_10.5.e003956.160) 2020; 21 2025072923350935000_10.5.e003956.68 2025072923350935000_10.5.e003956.69 Queirolo (2025072923350935000_10.5.e003956.131) 2017; 59 2025072923350935000_10.5.e003956.70 2025072923350935000_10.5.e003956.72 2025072923350935000_10.5.e003956.78 Hellmann (2025072923350935000_10.5.e003956.42) 2019; 381 2025072923350935000_10.5.e003956.75 Chen (2025072923350935000_10.5.e003956.21) 2013; 39 2025072923350935000_10.5.e003956.59 2025072923350935000_10.5.e003956.62 2025072923350935000_10.5.e003956.61 2025072923350935000_10.5.e003956.66 2025072923350935000_10.5.e003956.67 2025072923350935000_10.5.e003956.65 2025072923350935000_10.5.e003956.48 Hollen (2025072923350935000_10.5.e003956.184) 1993; 29A Suppl 1 2025072923350935000_10.5.e003956.4 2025072923350935000_10.5.e003956.3 2025072923350935000_10.5.e003956.2 2025072923350935000_10.5.e003956.47 2025072923350935000_10.5.e003956.1 2025072923350935000_10.5.e003956.9 2025072923350935000_10.5.e003956.8 2025072923350935000_10.5.e003956.7 2025072923350935000_10.5.e003956.6 2025072923350935000_10.5.e003956.51 Makharadze (2025072923350935000_10.5.e003956.83) 2023; 18 2025072923350935000_10.5.e003956.52 2025072923350935000_10.5.e003956.50 2025072923350935000_10.5.e003956.56 2025072923350935000_10.5.e003956.54 2025072923350935000_10.5.e003956.37 2025072923350935000_10.5.e003956.38 2025072923350935000_10.5.e003956.35 Ettinger (2025072923350935000_10.5.e003956.55) 2018; 16 Di Giacomo (2025072923350935000_10.5.e003956.132) 2009; 58 Rimm (2025072923350935000_10.5.e003956.46) 2017; 3 Vuong (2025072923350935000_10.5.e003956.60) 2020; 15 2025072923350935000_10.5.e003956.127 2025072923350935000_10.5.e003956.40 2025072923350935000_10.5.e003956.125 Krummel (2025072923350935000_10.5.e003956.22) 1995; 182 2025072923350935000_10.5.e003956.123 2025072923350935000_10.5.e003956.124 2025072923350935000_10.5.e003956.44 2025072923350935000_10.5.e003956.121 2025072923350935000_10.5.e003956.45 2025072923350935000_10.5.e003956.122 2025072923350935000_10.5.e003956.43 2025072923350935000_10.5.e003956.120 2025072923350935000_10.5.e003956.26 Sul (2025072923350935000_10.5.e003956.73) 2016; 21 2025072923350935000_10.5.e003956.27 2025072923350935000_10.5.e003956.24 2025072923350935000_10.5.e003956.25 2025072923350935000_10.5.e003956.28 2025072923350935000_10.5.e003956.29 Antonia (2025072923350935000_10.5.e003956.86) 2018; 379 Forde (2025072923350935000_10.5.e003956.126) 2021; 27 2025072923350935000_10.5.e003956.118 2025072923350935000_10.5.e003956.119 2025072923350935000_10.5.e003956.116 2025072923350935000_10.5.e003956.117 2025072923350935000_10.5.e003956.114 2025072923350935000_10.5.e003956.30 2025072923350935000_10.5.e003956.115 2025072923350935000_10.5.e003956.113 2025072923350935000_10.5.e003956.33 2025072923350935000_10.5.e003956.110 2025072923350935000_10.5.e003956.34 2025072923350935000_10.5.e003956.111 2025072923350935000_10.5.e003956.31 2025072923350935000_10.5.e003956.15 2025072923350935000_10.5.e003956.16 2025072923350935000_10.5.e003956.14 2025072923350935000_10.5.e003956.19 2025072923350935000_10.5.e003956.17 2025072923350935000_10.5.e003956.18 Herbst (2025072923350935000_10.5.e003956.74) 2020; 38 Spicer (2025072923350935000_10.5.e003956.90) 2021; 39 Naidoo (2025072923350935000_10.5.e003956.157) 2017; 35 2025072923350935000_10.5.e003956.109 2025072923350935000_10.5.e003956.107 2025072923350935000_10.5.e003956.108 2025072923350935000_10.5.e003956.105 2025072923350935000_10.5.e003956.106 2025072923350935000_10.5.e003956.101 Nakanishi (2025072923350935000_10.5.e003956.162) 2019; 57 2025072923350935000_10.5.e003956.102 2025072923350935000_10.5.e003956.23 2025072923350935000_10.5.e003956.20 Cheng (2025072923350935000_10.5.e003956.100) 2024; 391 Haspinger (2025072923350935000_10.5.e003956.58) 2015; 94 Vokes (2025072923350935000_10.5.e003956.81) 2018; 29 Leung (2025072923350935000_10.5.e003956.174) 2019; 28 Paz-Ares (2025072923350935000_10.5.e003956.5) 2021; 39 Rudin (2025072923350935000_10.5.e003956.103) 2020; 38 2025072923350935000_10.5.e003956.11 2025072923350935000_10.5.e003956.12 2025072923350935000_10.5.e003956.10 2025072923350935000_10.5.e003956.161 Hansen (2025072923350935000_10.5.e003956.188) 2020; 126 Eisenhauer (2025072923350935000_10.5.e003956.128) 2009; 45 Creelan (2025072923350935000_10.5.e003956.63) 2021; 124 Chiou (2025072923350935000_10.5.e003956.130) 2015; 33 2025072923350935000_10.5.e003956.169 Barlesi (2025072923350935000_10.5.e003956.150) 2019; 14 2025072923350935000_10.5.e003956.167 2025072923350935000_10.5.e003956.165 2025072923350935000_10.5.e003956.166 2025072923350935000_10.5.e003956.164 Bonneville (2025072923350935000_10.5.e003956.49) 2017; 2017 Socinski (2025072923350935000_10.5.e003956.77) 2018; 378 2025072923350935000_10.5.e003956.158 2025072923350935000_10.5.e003956.159 2025072923350935000_10.5.e003956.156 2025072923350935000_10.5.e003956.155 2025072923350935000_10.5.e003956.152 2025072923350935000_10.5.e003956.153 2025072923350935000_10.5.e003956.140 Win (2025072923350935000_10.5.e003956.170) 2005; 60 Midha (2025072923350935000_10.5.e003956.53) 2016; 34 Mazurek (2025072923350935000_10.5.e003956.112) 2017; 66 2025072923350935000_10.5.e003956.148 Keam (2025072923350935000_10.5.e003956.32) 2023; 83 Paz-Ares (2025072923350935000_10.5.e003956.76) 2020; 15 2025072923350935000_10.5.e003956.145 Takahashi (2025072923350935000_10.5.e003956.98) 2017; 18 2025072923350935000_10.5.e003956.143 2025072923350935000_10.5.e003956.144 2025072923350935000_10.5.e003956.141 2025072923350935000_10.5.e003956.142 Sung (2025072923350935000_10.5.e003956.168) 2017; 18 Forde (2025072923350935000_10.5.e003956.89) 2021; 81 2025072923350935000_10.5.e003956.138 2025072923350935000_10.5.e003956.139 2025072923350935000_10.5.e003956.137 2025072923350935000_10.5.e003956.135 2025072923350935000_10.5.e003956.133 Brahmer (2025072923350935000_10.5.e003956.154) 2018; 36 |
| References_xml | – volume: 18 start-page: 755 year: 2023 ident: R83 article-title: Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2023.03.008 – volume: 398 start-page: 1344 year: 2021 ident: R88 article-title: Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(21)02098-5 – volume: 18 year: 2021 ident: R39 article-title: PD-L1 as a biomarker of response to immune-checkpoint inhibitors publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-021-00473-5 – volume: 92 start-page: 205 year: 2000 ident: R127 article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.3.205 – volume: 35 year: 2019 ident: R164 article-title: Patient education issues and strategies associated with immunotherapy publication-title: Semin Oncol Nurs doi: 10.1016/j.soncn.2019.08.012 – volume: 378 start-page: 2093 year: 2018 ident: R51 article-title: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden publication-title: N Engl J Med doi: 10.1056/NEJMoa1801946 – volume: 196 start-page: 23 year: 2015 ident: R115 article-title: Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database publication-title: J Surg Res doi: 10.1016/j.jss.2015.01.043 – volume: 4 start-page: 1543 year: 2018 ident: R142 article-title: Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.3676 – volume: 124 start-page: 383 year: 2021 ident: R63 article-title: A phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer publication-title: Br J Cancer doi: 10.1038/s41416-020-01099-7 – volume: 17 start-page: 883 year: 2016 ident: R107 article-title: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30098-5 – volume: 29 start-page: iv192 year: 2018 ident: R54 article-title: Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Annals of Oncology doi: 10.1093/annonc/mdy275 – volume: 379 start-page: 2342 year: 2018 ident: R86 article-title: Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC publication-title: N Engl J Med Overseas Ed doi: 10.1056/NEJMoa1809697 – volume: 39 start-page: 2339 year: 2021 ident: R69 article-title: Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50 publication-title: J Clin Oncol doi: 10.1200/JCO.21.00174 – volume: 389 start-page: 2063 year: 2023 ident: R106 article-title: Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa2307980 – volume: 375 start-page: 1823 year: 2016 ident: R67 article-title: Pembrolizumab versus chemotherapy for PD-L1–Positive Non–Small-Cell lung cancer publication-title: N Engl J Med Overseas Ed doi: 10.1056/NEJMoa1606774 – volume: 18 start-page: 1600 year: 2017 ident: R189 article-title: Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30690-3 – volume: 4 start-page: 253 year: 2018 ident: R70 article-title: Clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.3808 – volume: 15 year: 2020 ident: R59 article-title: Alk inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis publication-title: PLoS One doi: 10.1371/journal.pone.0229179 – volume: 397 start-page: 375 year: 2021 ident: R124 article-title: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(20)32714-8 – volume: 18 start-page: 637 year: 2014 ident: R163 article-title: Chemotherapy education for patients with cancer: a literature review publication-title: Clin J Oncol Nurs doi: 10.1188/14.CJON.637-640 – volume: 22 start-page: 745 year: 2013 ident: R179 article-title: Associations between cancer-related financial stress and strain and psychological well-being among individuals living with cancer publication-title: Psychooncology doi: 10.1002/pon.3055 – volume: 126 start-page: 1550 year: 2020 ident: R188 article-title: Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): a toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs publication-title: Cancer doi: 10.1002/cncr.32692 – volume: 12 start-page: 1355 year: 2023 ident: R105 article-title: Tarlatamab: the promising immunotherapy on its way from the lab to the clinic publication-title: Transl Lung Cancer Res doi: 10.21037/tlcr-23-115 – volume: 38 start-page: 9001 year: 2020 ident: R27 article-title: KEYNOTE-604: pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC) publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2020.38.15_suppl.9001 – volume: 36 start-page: 1714 year: 2018 ident: R154 article-title: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline publication-title: J Clin Oncol doi: 10.1200/JCO.2017.77.6385 – volume: 11 start-page: 145 year: 2015 ident: R178 article-title: Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study publication-title: J Oncol Pract doi: 10.1200/JOP.2014.001542 – volume: 39 start-page: 98 year: 2016 ident: R31 article-title: Ctla-4 and PD-1 pathways: similarities, differences, and implications of their inhibition publication-title: Am J Clin Oncol doi: 10.1097/COC.0000000000000239 – volume: 16 start-page: 594 year: 2018 ident: R153 article-title: New NCCN guidelines: recognition and management of Immunotherapy-Related toxicity publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2018.0047 – volume: 29A Suppl 1 start-page: S51 year: 1993 ident: R184 article-title: Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS) publication-title: Eur J Cancer doi: 10.1016/S0959-8049(05)80262-X – volume: 41 start-page: 1213 year: 2023 ident: R15 article-title: Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study publication-title: J Clin Oncol – volume: 37 start-page: 1927 year: 2019 ident: R149 article-title: Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus Nonpalliative indications publication-title: J Clin Oncol doi: 10.1200/JCO.19.00189 – volume: 11 start-page: 570 year: 1993 ident: R183 article-title: The functional assessment of cancer therapy scale: development and validation of the general measure publication-title: J Clin Oncol doi: 10.1200/JCO.1993.11.3.570 – volume: 109 start-page: 2301 year: 2013 ident: R172 article-title: Quality of life during chemotherapy in lung cancer patients: results across different treatment lines publication-title: Br J Cancer doi: 10.1038/bjc.2013.585 – volume: 36 start-page: 911 year: 2018 ident: R57 article-title: Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of clinical oncology endorsement of the College of American pathologists/international association for the study of lung cancer/association for molecular pathology clinical practice guideline update publication-title: J Clin Oncol doi: 10.1200/JCO.2017.76.7293 – volume: 14 start-page: S214 year: 2019 ident: R150 article-title: OA04.02 CheckMate 817: first-line nivolumab + ipilimumab in patients with ECoG PS 2 and other special populations with advanced NSCLC publication-title: Journal of Thoracic Oncology doi: 10.1016/j.jtho.2019.08.424 – volume: 28 start-page: 815 year: 2019 ident: R174 article-title: Assessing the psychosocial needs of newly diagnosed patients with nonsmall cell lung cancer: identifying factors associated with distress publication-title: Psychooncology doi: 10.1002/pon.5025 – volume: 66 start-page: 214 year: 2017 ident: R112 article-title: Malignant Mesothelioma Mortality - United States, 1999-2015 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm6608a3 – volume: 8 start-page: S153 year: 2019 ident: R96 article-title: What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era? publication-title: Transl Lung Cancer Res doi: 10.21037/tlcr.2019.05.01 – volume: 36 start-page: 1905 year: 2018 ident: R145 article-title: Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders publication-title: J Clin Oncol doi: 10.1200/JCO.2017.77.0305 – volume: 39 year: 2021 ident: R90 article-title: Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC) publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2021.39.15_suppl.8503 – volume: 83 start-page: 8 year: 2000 ident: R93 article-title: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent publication-title: Br J Cancer doi: 10.1054/bjoc.2000.1164 – volume: 7 start-page: 387 year: 2019 ident: R26 article-title: Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(19)30084-0 – volume: 45 start-page: 228 year: 2009 ident: R128 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 391 start-page: 1313 year: 2024 ident: R100 article-title: Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa2404873 – volume: 32 start-page: 1626 year: 2021 ident: R52 article-title: Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the friends of cancer research TMB harmonization project publication-title: Ann Oncol doi: 10.1016/j.annonc.2021.09.016 – volume: 105 start-page: 3005 year: 2008 ident: R133 article-title: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0712237105 – volume: 12 start-page: 208 year: 2017 ident: R47 article-title: PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.11.2228 – volume: 59 start-page: 71 year: 2017 ident: R131 article-title: Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2017.07.002 – volume: 29 start-page: 959 year: 2018 ident: R81 article-title: Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases publication-title: Ann Oncol doi: 10.1093/annonc/mdy041 – volume: 10 year: 2012 ident: R119 article-title: BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs publication-title: J Transl Med doi: 10.1186/1479-5876-10-179 – volume: 30 start-page: v710 year: 2019 ident: R13 article-title: IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) publication-title: Annals of Oncology doi: 10.1093/annonc/mdz264 – volume: 15 start-page: 618 year: 2020 ident: R110 article-title: Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2019.12.109 – volume: 92 start-page: 974 year: 2013 ident: R121 article-title: Germline BAP1 mutations predispose to renal cell carcinomas publication-title: Am J Hum Genet doi: 10.1016/j.ajhg.2013.04.012 – volume: 58 start-page: 1297 year: 2009 ident: R132 article-title: Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-008-0642-y – volume: 7 start-page: 1420 year: 2017 ident: R33 article-title: Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-17-0593 – volume: 94 start-page: 213 year: 2015 ident: R58 article-title: Is there evidence for different effects among EGFR-TKIs? systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2014.11.005 – volume: 81 start-page: 288 year: 2013 ident: R167 article-title: Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany publication-title: Lung Cancer doi: 10.1016/j.lungcan.2013.03.008 – volume: 80 start-page: CT221 year: 2020 ident: R72 article-title: Abstract CT221: nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: results from CheckMate 227 publication-title: Cancer Research – volume: 16 start-page: 807 year: 2018 ident: R55 article-title: NCCN guidelines insights: non-small cell lung cancer, version 5.2018 publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2018.0062 – volume: 8 start-page: 98524 year: 2017 ident: R48 article-title: PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study publication-title: Oncotarget doi: 10.18632/oncotarget.21567 – volume: 20 start-page: 924 year: 2019 ident: R6 article-title: Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30167-6 – volume: 12 start-page: 337 year: 1994 ident: R20 article-title: Tumor antigens recognized by T lymphocytes publication-title: Annu Rev Immunol doi: 10.1146/annurev.iy.12.040194.002005 – volume: 11 start-page: 3887 year: 1992 ident: R25 article-title: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death publication-title: Embo J doi: 10.1002/j.1460-2075.1992.tb05481.x – volume: 22 start-page: 51 year: 2021 ident: R102 article-title: Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (Caspian): updated results from a randomised, controlled, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30539-8 – volume: 2 start-page: e192535- year: 2019 ident: R36 article-title: Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2019.2535 – volume: 16 start-page: 1909 year: 2021 ident: R78 article-title: IMpower150 final overall survival analyses for Atezolizumab plus bevacizumab and chemotherapy in first-line metastatic Nonsquamous NSCLC publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2021.07.009 – volume: 18 start-page: e143 year: 2017 ident: R136 article-title: iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30074-8 – volume: 17 start-page: 750 year: 2019 ident: R144 article-title: Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2019.7310 – volume: 9 start-page: 1023 year: 2016 ident: R175 article-title: Quality of life of patients with lung cancer publication-title: Onco Targets Ther doi: 10.2147/OTT.S100685 – volume: 34 start-page: 3025 year: 2016 ident: R53 article-title: Pd-L1 expression in advanced NSCLC: primary lesions versus metastatic sites and impact of sample age publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2016.34.15_suppl.3025 – volume: 378 start-page: 2288 year: 2018 ident: R77 article-title: Atezolizumab for first-line treatment of metastatic Nonsquamous NSCLC publication-title: N Engl J Med doi: 10.1056/NEJMoa1716948 – volume: 13 start-page: 1156 year: 2018 ident: R80 article-title: Updated efficacy analysis including secondary population results for oak: a randomized phase III study of Atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.04.039 – year: 2022 ident: R125 article-title: First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.01.074 – volume: 14 start-page: 494 year: 2019 ident: R159 article-title: Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.11.016 – volume: 31 start-page: 11 year: 2004 ident: R186 article-title: The functional assessment of cancer therapy-lung and lung cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2004.04.008 – volume: 387 start-page: 1540 year: 2016 ident: R7 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(15)01281-7 – volume: 389 start-page: 1672 year: 2023 ident: R91 article-title: Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa2304875 – volume: 13 start-page: 1930 year: 2018 ident: R158 article-title: Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.08.2035 – volume: 30 start-page: 1321 year: 2019 ident: R61 article-title: Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry publication-title: Ann Oncol doi: 10.1093/annonc/mdz167 – volume: 15 start-page: 589 year: 2020 ident: R60 article-title: Efficacy and safety of crizotinib in the treatment of advanced non-small-cell lung cancer with ROS1 rearrangement or Met alteration: a systematic review and meta-analysis publication-title: Target Oncol doi: 10.1007/s11523-020-00745-7 – volume: 38 start-page: 2369 year: 2020 ident: R103 article-title: Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study publication-title: J Clin Oncol doi: 10.1200/JCO.20.00793 – volume: 402 start-page: 2295 year: 2023 ident: R18 article-title: Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(23)01613-6 – volume: 18 start-page: 663 year: 2017 ident: R98 article-title: Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30230-9 – volume: 10 year: 2019 ident: R176 article-title: Suicide among cancer patients publication-title: Nat Commun doi: 10.1038/s41467-018-08170-1 – volume: 25 start-page: 266 year: 2024 ident: R85 article-title: A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2024.03.003 – volume: 11 year: 2021 ident: R64 article-title: Front-Line ICI-Based combination therapy Post-TKI resistance may improve survival in NSCLC patients with EGFR mutation publication-title: Front Oncol doi: 10.3389/fonc.2021.739090 – volume: 19 start-page: 672 year: 2018 ident: R99 article-title: Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30139-6 – volume: 378 start-page: 1976 year: 2018 ident: R143 article-title: Neoadjuvant PD-1 blockade in resectable lung cancer publication-title: N Engl J Med Overseas Ed doi: 10.1056/NEJMoa1716078 – volume: 62 start-page: 132 year: 2016 ident: R129 article-title: RECIST 1.1-Update and clarification: from the RECIST committee publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.03.081 – volume: 30 start-page: 171 year: 2019 ident: R56 article-title: Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, mos, Sso and TOS publication-title: Ann Oncol doi: 10.1093/annonc/mdy554 – volume: 35 start-page: 709 year: 2017 ident: R157 article-title: Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2016.68.2005 – volume: 18 start-page: 274 year: 2017 ident: R168 article-title: Evolution of symptom burden of advanced lung cancer over a decade publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2016.12.010 – volume: 28 start-page: 1043 year: 2015 ident: R117 article-title: BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations publication-title: Mod Pathol doi: 10.1038/modpathol.2015.65 – volume: 7 start-page: 106 year: 2019 ident: R147 article-title: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0585-1 – volume: 23 start-page: 1274 year: 2022 ident: R17 article-title: Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(22)00518-6 – volume: 38 start-page: 1580 year: 2020 ident: R74 article-title: Long-term outcomes and retreatment among patients with previously treated, programmed Death-Ligand 1‒Positive, advanced Non‒Small-Cell lung cancer in the KEYNOTE-010 study publication-title: J Clin Oncol doi: 10.1200/JCO.19.02446 – volume: 16 start-page: 16 year: 2009 ident: R171 article-title: Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: a literature review publication-title: Curr Oncol doi: 10.3747/co.v16i2.376 – volume: 39 start-page: 1349 year: 2021 ident: R109 article-title: Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451 publication-title: J Clin Oncol doi: 10.1200/JCO.20.02212 – volume: 81 start-page: CT003 year: 2021 ident: R89 article-title: Abstract CT003: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial publication-title: Cancer Res doi: 10.1158/1538-7445.AM2021-CT003 – volume: 13 start-page: 1302 year: 2018 ident: R45 article-title: Pd-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.05.013 – volume: 6 start-page: 8 year: 2020 ident: R187 article-title: Development of a functional assessment of chronic illness therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators publication-title: J Cancer Metastasis Treat doi: 10.20517/2394-4722.2019.38 – volume: 390 start-page: 1756 year: 2024 ident: R92 article-title: Perioperative Nivolumab in Resectable Lung Cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa2311926 – volume: 26 start-page: 4617 year: 2008 ident: R66 article-title: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials publication-title: J Clin Oncol doi: 10.1200/JCO.2008.17.7162 – volume: 22 start-page: 1392 year: 2017 ident: R75 article-title: FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond publication-title: Oncologist doi: 10.1634/theoncologist.2017-0078 – volume: 19 start-page: 441 year: 2018 ident: R190 article-title: Patient-reported outcomes in oak: a phase III study of Atezolizumab versus docetaxel in advanced non-small-cell lung cancer publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2018.05.011 – volume: 393 start-page: 1819 year: 2019 ident: R8 article-title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(18)32409-7 – volume: 394 start-page: 1929 year: 2019 ident: R101 article-title: Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (Caspian): a randomised, controlled, open-label, phase 3 trial publication-title: The Lancet doi: 10.1016/S0140-6736(19)32222-6 – volume: 379 start-page: 2220 year: 2018 ident: R193 article-title: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1809064 – volume: 31 start-page: 798 year: 2020 ident: R87 article-title: Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the Pacific trial publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.03.287 – volume: 9 start-page: 1243 year: 2014 ident: R166 article-title: An evidence-based determination of issues affecting quality of life and patient-reported outcomes in lung cancer: results of a survey of 660 patients publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000244 – volume: 5 start-page: 95 year: 2017 ident: R151 article-title: Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working group publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0300-z – volume: 141 start-page: 343 year: 2012 ident: R169 article-title: Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age publication-title: J Affect Disord doi: 10.1016/j.jad.2012.03.025 – volume: 4 start-page: 1112 year: 2018 ident: R65 article-title: EGFR-TKI-Associated interstitial pneumonitis in Nivolumab-Treated patients with non-small cell lung cancer publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.4526 – volume: 381 start-page: 2020 year: 2019 ident: R42 article-title: Nivolumab plus ipilimumab in advanced Non–Small-Cell lung cancer publication-title: N Engl J Med Overseas Ed doi: 10.1056/NEJMoa1910231 – volume: 34 start-page: 3984 year: 2016 ident: R177 article-title: Longitudinal changes in depression symptoms and survival among patients with lung cancer: a national cohort assessment publication-title: J Clin Oncol doi: 10.1200/JCO.2016.66.8459 – volume: 13 start-page: 978 year: 2018 ident: R140 article-title: Radiologic pseudoprogression during anti-PD-1 therapy for advanced non-small cell lung cancer publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.04.010 – volume: 30 start-page: ii38 year: 2019 ident: R192 article-title: Final analysis of the phase 3 KEYNOTE-042 study: pembrolizumab (PEMBRO) versus platinum-based chemotherapy (chemo) as first-line therapy for patients (PTS) with PD-L1–POSITIVE locally advanced/metastatic NSCLC publication-title: Ann Oncol doi: 10.1093/annonc/mdz063 – volume: 68 start-page: 394 year: 2018 ident: R1 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin doi: 10.3322/caac.21492 – volume: 33 start-page: 3541 year: 2015 ident: R130 article-title: Pseudoprogression and immune-related response in solid tumors publication-title: J Clin Oncol doi: 10.1200/JCO.2015.61.6870 – volume: 8 start-page: 239 year: 2007 ident: R24 article-title: The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection publication-title: Nat Immunol doi: 10.1038/ni1443 – volume: 37 start-page: 537 year: 2019 ident: R68 article-title: Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater publication-title: J Clin Oncol doi: 10.1200/JCO.18.00149 – volume: 39 year: 2021 ident: R71 article-title: Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2021.39.15_suppl.9001 – volume: 327 start-page: 1618 year: 1992 ident: R94 article-title: A meta-analysis of thoracic radiotherapy for small-cell lung cancer publication-title: N Engl J Med Overseas Ed doi: 10.1056/NEJM199212033272302 – volume: 20 year: 2019 ident: R148 article-title: Programmed cell death 1 (PD-1) inhibitors in renal transplant patients with advanced cancer: a double-edged sword? publication-title: Int J Mol Sci doi: 10.3390/ijms20092194 – volume: 36 start-page: 850 year: 2018 ident: R137 article-title: Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.2017.75.1644 – volume: 33 start-page: 380 year: 2020 ident: R43 article-title: Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis publication-title: Mod Pathol doi: 10.1038/s41379-019-0349-y – volume: 5 start-page: 557 year: 2008 ident: R134 article-title: CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS publication-title: Nat Clin Pract Oncol doi: 10.1038/ncponc1183 – volume: 161 start-page: 205 year: 2015 ident: R23 article-title: Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential publication-title: Cell doi: 10.1016/j.cell.2015.03.030 – volume: 2017 start-page: 1 year: 2017 ident: R49 article-title: Landscape of microsatellite instability across 39 cancer types publication-title: JCO Precis Oncol doi: 10.1200/PO.17.00073 – volume: 8 year: 2020 ident: R34 article-title: Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance Taskforce publication-title: J Immunother Cancer doi: 10.1136/jitc-2019-000398 – volume: 60 start-page: 234 year: 2005 ident: R170 article-title: Effect of lung cancer surgery on quality of life publication-title: Thorax doi: 10.1136/thx.2004.031872 – volume: 383 start-page: 1328 year: 2020 ident: R41 article-title: Atezolizumab for first-line treatment of PD-L1-Selected patients with NSCLC publication-title: N Engl J Med doi: 10.1056/NEJMoa1917346 – volume: 72 start-page: 7 year: 2022 ident: R2 article-title: Cancer statistics, 2022 publication-title: CA Cancer J Clin doi: 10.3322/caac.21708 – volume: 15 start-page: 1657 year: 2020 ident: R76 article-title: A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-Specified final analysis of KEYNOTE-407 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2020.06.015 – volume: 15 start-page: 7412 year: 2009 ident: R135 article-title: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-1624 – volume: 397 start-page: 375 year: 2021 ident: R14 article-title: First-Line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial publication-title: The Lancet doi: 10.1016/S0140-6736(20)32714-8 – volume: 39 start-page: 723 year: 2021 ident: R82 article-title: Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.20.01605 – volume: 57 start-page: 451 year: 2019 ident: R162 article-title: Pre-Existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer publication-title: Respir Investig doi: 10.1016/j.resinv.2019.05.002 – volume: 13 start-page: 1012 year: 2018 ident: R139 article-title: Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1) publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.04.034 – volume: 14 start-page: 553 year: 2019 ident: R62 article-title: Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.11.028 – volume: 19 start-page: 3936 year: 2013 ident: R138 article-title: Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-0895 – volume: 397 start-page: 592 year: 2021 ident: R11 article-title: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(21)00228-2 – volume: 15 start-page: 288 year: 2020 ident: R4 article-title: Three-Year overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC-Update from Pacific publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2019.10.002 – volume: 389 start-page: 491 year: 2023 ident: R16 article-title: Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa2302983 – volume: 21 start-page: 2636 year: 2003 ident: R122 article-title: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma publication-title: J Clin Oncol doi: 10.1200/JCO.2003.11.136 – volume: 12 start-page: 199 year: 1995 ident: R185 article-title: Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument publication-title: Lung Cancer doi: 10.1016/0169-5002(95)00450-F – volume: 18 start-page: 497 year: 2017 ident: R173 article-title: Emotional problems, quality of life, and symptom burden in patients with lung cancer publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2017.02.008 – volume: 83 start-page: 93 year: 2023 ident: R32 article-title: Tremelimumab: First Approval publication-title: Drugs (Abingdon Engl) doi: 10.1007/s40265-022-01827-8 – volume: 2 start-page: 1607 year: 2016 ident: R161 article-title: Incidence of programmed cell death 1 Inhibitor-Related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2016.2453 – volume: 18 start-page: 381 year: 2013 ident: R180 article-title: The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience publication-title: Oncologist doi: 10.1634/theoncologist.2012-0279 – volume: 376 start-page: 191 year: 2017 ident: R146 article-title: Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab publication-title: N Engl J Med doi: 10.1056/NEJMc1614298 – volume: 21 start-page: e169 year: 2020 ident: R160 article-title: Lower survival in patients who develop pneumonitis following immunotherapy for lung cancer publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2019.10.009 – volume: 86 start-page: 133 year: 2014 ident: R116 article-title: Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials publication-title: Lung Cancer doi: 10.1016/j.lungcan.2014.08.017 – volume: 19 start-page: 535 year: 2017 ident: R120 article-title: Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas publication-title: Neuro Oncol doi: 10.1093/neuonc/now235 – volume: 20 start-page: e470 year: 2019 ident: R97 article-title: Relationship between prior radiotherapy and Checkpoint-Inhibitor pneumonitis in patients with advanced non-small-cell lung cancer publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2019.02.018 – volume: 38 start-page: 9501 year: 2020 ident: R28 article-title: Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2020.38.15_suppl.9501 – volume: 22 start-page: 198 year: 2021 ident: R12 article-title: First-Line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30641-0 – volume: 10 start-page: 158 year: 2020 ident: R95 article-title: Radiation therapy for small cell lung cancer: an ASTRO clinical practice guideline publication-title: Pract Radiat Oncol doi: 10.1016/j.prro.2020.02.009 – volume: 27 start-page: 1910 year: 2021 ident: R126 article-title: Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial publication-title: Nat Med doi: 10.1038/s41591-021-01541-0 – volume: 6 start-page: 75 year: 2018 ident: R191 article-title: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0382-2 – volume: 38 start-page: 1505 year: 2020 ident: R9 article-title: Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic Nonsquamous non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.19.03136 – volume: 35 start-page: 3924 year: 2017 ident: R10 article-title: Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057) publication-title: J Clin Oncol doi: 10.1200/JCO.2017.74.3062 – volume: 39 start-page: 1 year: 2013 ident: R21 article-title: Oncology meets immunology: the cancer-immunity cycle publication-title: Immunity doi: 10.1016/j.immuni.2013.07.012 – volume: 27 start-page: 504 year: 2021 ident: R141 article-title: Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial publication-title: Nat Med doi: 10.1038/s41591-020-01224-2 – volume: 21 start-page: 643 year: 2016 ident: R73 article-title: FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed Death-Ligand 1 publication-title: Oncologist doi: 10.1634/theoncologist.2015-0498 – volume: 7 start-page: 165 year: 2019 ident: R156 article-title: Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0645-6 – volume: 3 start-page: 1051 year: 2017 ident: R46 article-title: A prospective, multi-institutional, Pathologist-Based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.0013 – volume: 387 start-page: 1405 year: 2016 ident: R123 article-title: Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin cisplatin pemetrexed study (maps): a randomised, controlled, open-label, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(15)01238-6 – volume: 9 year: 2021 ident: R152 article-title: Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events publication-title: J Immunother Cancer doi: 10.1136/jitc-2021-002435 – volume: 182 start-page: 459 year: 1995 ident: R22 article-title: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation publication-title: J Exp Med doi: 10.1084/jem.182.2.459 – volume: 32 start-page: 631 year: 2021 ident: R108 article-title: Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆ publication-title: Ann Oncol doi: 10.1016/j.annonc.2021.01.071 – volume: 26 start-page: 79 year: 2020 ident: R38 article-title: The clinicopathological and molecular associations of PD-L1 expression in non-small cell lung cancer: analysis of a series of 10,005 cases tested with the 22C3 assay publication-title: Pathol Oncol Res doi: 10.1007/s12253-018-0469-6 – volume: 2017 start-page: 1 year: 2017 ident: R118 article-title: Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis? publication-title: Dis Markers doi: 10.1155/2017/1310478 – volume: 39 start-page: 9016 year: 2021 ident: R5 article-title: Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2021.39.15_suppl.9016 – volume: 16 start-page: 145 year: 1998 ident: R114 article-title: Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience publication-title: J Clin Oncol doi: 10.1200/JCO.1998.16.1.145 – volume: 6 start-page: 5 year: 2013 ident: R165 article-title: Real-world impact of education: treating patients with ipilimumab in a community practice setting publication-title: Cancer Manag Res doi: 10.2147/CMAR.S52543 – volume: 25 start-page: 4691 year: 2019 ident: R50 article-title: Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-0624 – volume: 38 year: 2020 ident: R104 article-title: Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (Ce) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2020.38.15_suppl.9000 – ident: 2025072923350935000_10.5.e003956.153 doi: 10.1016/j.lungcan.2013.03.008 – ident: 2025072923350935000_10.5.e003956.70 doi: 10.1056/NEJMoa1716948 – volume: 31 start-page: 11 year: 2004 ident: 2025072923350935000_10.5.e003956.186 article-title: The functional assessment of cancer therapy-lung and lung cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2004.04.008 – ident: 2025072923350935000_10.5.e003956.37 – volume: 18 year: 2021 ident: 2025072923350935000_10.5.e003956.39 article-title: PD-L1 as a biomarker of response to immune-checkpoint inhibitors publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-021-00473-5 – ident: 2025072923350935000_10.5.e003956.108 doi: 10.1200/JCO.2003.11.136 – ident: 2025072923350935000_10.5.e003956.1 doi: 10.3322/caac.21492 – ident: 2025072923350935000_10.5.e003956.10 doi: 10.1200/JCO.2017.74.3062 – volume: 378 start-page: 2288 year: 2018 ident: 2025072923350935000_10.5.e003956.77 article-title: Atezolizumab for first-line treatment of metastatic Nonsquamous NSCLC publication-title: N Engl J Med doi: 10.1056/NEJMoa1716948 – ident: 2025072923350935000_10.5.e003956.84 – ident: 2025072923350935000_10.5.e003956.182 – ident: 2025072923350935000_10.5.e003956.17 doi: 10.1084/jem.182.2.459 – ident: 2025072923350935000_10.5.e003956.18 doi: 10.1016/j.cell.2015.03.030 – ident: 2025072923350935000_10.5.e003956.26 doi: 10.1158/2159-8290.CD-17-0593 – ident: 2025072923350935000_10.5.e003956.99 doi: 10.1016/S1470-2045(18)30139-6 – ident: 2025072923350935000_10.5.e003956.113 – ident: 2025072923350935000_10.5.e003956.20 doi: 10.1002/j.1460-2075.1992.tb05481.x – volume: 11 year: 2021 ident: 2025072923350935000_10.5.e003956.64 article-title: Front-Line ICI-Based combination therapy Post-TKI resistance may improve survival in NSCLC patients with EGFR mutation publication-title: Front Oncol doi: 10.3389/fonc.2021.739090 – ident: 2025072923350935000_10.5.e003956.92 doi: 10.1200/JCO.2020.38.15_suppl.9000 – ident: 2025072923350935000_10.5.e003956.143 doi: 10.1200/JCO.2016.68.2005 – volume: 29 start-page: 959 year: 2018 ident: 2025072923350935000_10.5.e003956.81 article-title: Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases publication-title: Ann Oncol doi: 10.1093/annonc/mdy041 – volume: 81 start-page: CT003 year: 2021 ident: 2025072923350935000_10.5.e003956.89 article-title: Abstract CT003: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial publication-title: Cancer Res doi: 10.1158/1538-7445.AM2021-CT003 – ident: 2025072923350935000_10.5.e003956.50 doi: 10.1200/JCO.2017.76.7293 – ident: 2025072923350935000_10.5.e003956.67 doi: 10.1200/JCO.19.02446 – volume: 38 start-page: 1580 year: 2020 ident: 2025072923350935000_10.5.e003956.74 article-title: Long-term outcomes and retreatment among patients with previously treated, programmed Death-Ligand 1‒Positive, advanced Non‒Small-Cell lung cancer in the KEYNOTE-010 study publication-title: J Clin Oncol doi: 10.1200/JCO.19.02446 – volume: 39 start-page: 9016 year: 2021 ident: 2025072923350935000_10.5.e003956.5 article-title: Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2021.39.15_suppl.9016 – ident: 2025072923350935000_10.5.e003956.19 – volume: 383 start-page: 1328 year: 2020 ident: 2025072923350935000_10.5.e003956.41 article-title: Atezolizumab for first-line treatment of PD-L1-Selected patients with NSCLC publication-title: N Engl J Med doi: 10.1056/NEJMoa1917346 – ident: 2025072923350935000_10.5.e003956.23 doi: 10.1016/j.cell.2015.03.030 – volume: 58 start-page: 1297 year: 2009 ident: 2025072923350935000_10.5.e003956.132 article-title: Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-008-0642-y – ident: 2025072923350935000_10.5.e003956.114 doi: 10.1016/j.ejca.2008.10.026 – ident: 2025072923350935000_10.5.e003956.189 doi: 10.1016/s1470-2045(17)30690-3 – volume: 94 start-page: 213 year: 2015 ident: 2025072923350935000_10.5.e003956.58 article-title: Is there evidence for different effects among EGFR-TKIs? systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2014.11.005 – volume: 33 start-page: 3541 year: 2015 ident: 2025072923350935000_10.5.e003956.130 article-title: Pseudoprogression and immune-related response in solid tumors publication-title: J Clin Oncol doi: 10.1200/JCO.2015.61.6870 – ident: 2025072923350935000_10.5.e003956.158 doi: 10.1038/bjc.2013.585 – volume: 391 start-page: 1313 year: 2024 ident: 2025072923350935000_10.5.e003956.100 article-title: Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa2404873 – volume: 57 start-page: 451 year: 2019 ident: 2025072923350935000_10.5.e003956.162 article-title: Pre-Existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer publication-title: Respir Investig doi: 10.1016/j.resinv.2019.05.002 – ident: 2025072923350935000_10.5.e003956.68 doi: 10.1634/theoncologist.2017-0078 – volume: 25 start-page: 266 year: 2024 ident: 2025072923350935000_10.5.e003956.85 article-title: A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2024.03.003 – volume: 30 start-page: ii38 year: 2019 ident: 2025072923350935000_10.5.e003956.192 article-title: Final analysis of the phase 3 KEYNOTE-042 study: pembrolizumab (PEMBRO) versus platinum-based chemotherapy (chemo) as first-line therapy for patients (PTS) with PD-L1–POSITIVE locally advanced/metastatic NSCLC publication-title: Ann Oncol doi: 10.1093/annonc/mdz063 – ident: 2025072923350935000_10.5.e003956.25 doi: 10.1097/COC.0000000000000239 – ident: 2025072923350935000_10.5.e003956.177 doi: 10.1186/s40425-018-0382-2 – volume: 6 start-page: 8 year: 2020 ident: 2025072923350935000_10.5.e003956.187 article-title: Development of a functional assessment of chronic illness therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators publication-title: J Cancer Metastasis Treat – ident: 2025072923350935000_10.5.e003956.38 doi: 10.1016/j.jtho.2018.05.013 – volume: 39 start-page: 1 year: 2013 ident: 2025072923350935000_10.5.e003956.21 article-title: Oncology meets immunology: the cancer-immunity cycle publication-title: Immunity doi: 10.1016/j.immuni.2013.07.012 – ident: 2025072923350935000_10.5.e003956.181 – ident: 2025072923350935000_10.5.e003956.164 doi: 10.1200/JOP.2014.001542 – ident: 2025072923350935000_10.5.e003956.102 doi: 10.1016/j.lungcan.2014.08.017 – volume: 28 start-page: 815 year: 2019 ident: 2025072923350935000_10.5.e003956.174 article-title: Assessing the psychosocial needs of newly diagnosed patients with nonsmall cell lung cancer: identifying factors associated with distress publication-title: Psychooncology doi: 10.1002/pon.5025 – volume: 5 start-page: 95 year: 2017 ident: 2025072923350935000_10.5.e003956.151 article-title: Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working group publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0300-z – ident: 2025072923350935000_10.5.e003956.6 doi: 10.1016/S1470-2045(19)30167-6 – volume: 15 start-page: 589 year: 2020 ident: 2025072923350935000_10.5.e003956.60 article-title: Efficacy and safety of crizotinib in the treatment of advanced non-small-cell lung cancer with ROS1 rearrangement or Met alteration: a systematic review and meta-analysis publication-title: Target Oncol doi: 10.1007/s11523-020-00745-7 – ident: 2025072923350935000_10.5.e003956.115 doi: 10.1016/j.ejca.2016.03.081 – volume: 36 start-page: 911 year: 2018 ident: 2025072923350935000_10.5.e003956.57 article-title: Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of clinical oncology endorsement of the College of American pathologists/international association for the study of lung cancer/association for molecular pathology clinical practice guideline update publication-title: J Clin Oncol doi: 10.1200/JCO.2017.76.7293 – ident: 2025072923350935000_10.5.e003956.171 doi: 10.1016/0169-5002(95)00450-F – ident: 2025072923350935000_10.5.e003956.109 doi: 10.1016/S0140-6736(15)01238-6 – volume: 15 start-page: 1657 year: 2020 ident: 2025072923350935000_10.5.e003956.76 article-title: A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-Specified final analysis of KEYNOTE-407 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2020.06.015 – ident: 2025072923350935000_10.5.e003956.169 doi: 10.1200/JCO.1993.11.3.570 – ident: 2025072923350935000_10.5.e003956.142 doi: 10.1186/s40425-019-0645-6 – ident: 2025072923350935000_10.5.e003956.105 doi: 10.1186/1479-5876-10-179 – volume: 18 start-page: 755 year: 2023 ident: 2025072923350935000_10.5.e003956.83 article-title: Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2023.03.008 – ident: 2025072923350935000_10.5.e003956.28 doi: 10.1200/JCO.2020.38.15_suppl.9501 – volume: 18 start-page: e143 year: 2017 ident: 2025072923350935000_10.5.e003956.136 article-title: iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30074-8 – ident: 2025072923350935000_10.5.e003956.167 doi: 10.1016/j.lungcan.2013.03.008 – volume: 30 start-page: v710 year: 2019 ident: 2025072923350935000_10.5.e003956.13 article-title: IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) publication-title: Annals of Oncology doi: 10.1093/annonc/mdz264 – volume: 11 start-page: 145 year: 2015 ident: 2025072923350935000_10.5.e003956.178 article-title: Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study publication-title: J Oncol Pract doi: 10.1200/JOP.2014.001542 – volume: 59 start-page: 71 year: 2017 ident: 2025072923350935000_10.5.e003956.131 article-title: Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2017.07.002 – ident: 2025072923350935000_10.5.e003956.176 doi: 10.1016/j.cllc.2018.05.011 – volume: 37 start-page: 1927 year: 2019 ident: 2025072923350935000_10.5.e003956.149 article-title: Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus Nonpalliative indications publication-title: J Clin Oncol doi: 10.1200/JCO.19.00189 – ident: 2025072923350935000_10.5.e003956.11 doi: 10.1016/S0140-6736(21)00228-2 – volume: 35 start-page: 709 year: 2017 ident: 2025072923350935000_10.5.e003956.157 article-title: Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2016.68.2005 – volume: 381 start-page: 2020 year: 2019 ident: 2025072923350935000_10.5.e003956.42 article-title: Nivolumab plus ipilimumab in advanced Non–Small-Cell lung cancer publication-title: N Engl J Med Overseas Ed doi: 10.1056/NEJMoa1910231 – ident: 2025072923350935000_10.5.e003956.82 doi: 10.1054/bjoc.2000.1164 – ident: 2025072923350935000_10.5.e003956.94 doi: 10.1016/j.annonc.2021.01.071 – ident: 2025072923350935000_10.5.e003956.156 doi: 10.1136/thx.2004.031872 – ident: 2025072923350935000_10.5.e003956.88 doi: 10.1016/S1470-2045(18)30139-6 – ident: 2025072923350935000_10.5.e003956.34 doi: 10.1056/NEJMoa1917346 – ident: 2025072923350935000_10.5.e003956.152 doi: 10.1097/JTO.0000000000000244 – volume: 109 start-page: 2301 year: 2013 ident: 2025072923350935000_10.5.e003956.172 article-title: Quality of life during chemotherapy in lung cancer patients: results across different treatment lines publication-title: Br J Cancer doi: 10.1038/bjc.2013.585 – ident: 2025072923350935000_10.5.e003956.9 doi: 10.1200/JCO.19.03136 – volume: 39 year: 2021 ident: 2025072923350935000_10.5.e003956.90 article-title: Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC) publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2021.39.15_suppl.8503 – ident: 2025072923350935000_10.5.e003956.123 doi: 10.1200/JCO.2017.75.1644 – ident: 2025072923350935000_10.5.e003956.59 doi: 10.1200/JCO.2008.17.7162 – ident: 2025072923350935000_10.5.e003956.44 – volume: 21 start-page: 643 year: 2016 ident: 2025072923350935000_10.5.e003956.73 article-title: FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed Death-Ligand 1 publication-title: Oncologist doi: 10.1634/theoncologist.2015-0498 – volume: 379 start-page: 2342 year: 2018 ident: 2025072923350935000_10.5.e003956.86 article-title: Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC publication-title: N Engl J Med Overseas Ed doi: 10.1056/NEJMoa1809697 – volume: 62 start-page: 132 year: 2016 ident: 2025072923350935000_10.5.e003956.129 article-title: RECIST 1.1-Update and clarification: from the RECIST committee publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.03.081 – ident: 2025072923350935000_10.5.e003956.14 doi: 10.1016/s0140-6736(20)32714-8 – volume: 36 start-page: 1714 year: 2018 ident: 2025072923350935000_10.5.e003956.154 article-title: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline publication-title: J Clin Oncol doi: 10.1200/JCO.2017.77.6385 – ident: 2025072923350935000_10.5.e003956.165 doi: 10.1002/pon.3055 – ident: 2025072923350935000_10.5.e003956.120 doi: 10.1038/ncponc1183 – ident: 2025072923350935000_10.5.e003956.51 doi: 10.1016/j.critrevonc.2014.11.005 – ident: 2025072923350935000_10.5.e003956.78 doi: 10.1016/j.jtho.2021.07.009 – ident: 2025072923350935000_10.5.e003956.107 doi: 10.1016/j.ajhg.2013.04.012 – ident: 2025072923350935000_10.5.e003956.179 doi: 10.1056/NEJMoa1809064 – ident: 2025072923350935000_10.5.e003956.122 doi: 10.1016/S1470-2045(17)30074-8 – ident: 2025072923350935000_10.5.e003956.15 doi: 10.1146/annurev.iy.12.040194.002005 – volume: 7 start-page: 106 year: 2019 ident: 2025072923350935000_10.5.e003956.147 article-title: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0585-1 – ident: 2025072923350935000_10.5.e003956.61 doi: 10.1200/JCO.18.00149 – ident: 2025072923350935000_10.5.e003956.148 doi: 10.1016/j.resinv.2019.05.002 – volume: 16 start-page: 807 year: 2018 ident: 2025072923350935000_10.5.e003956.55 article-title: NCCN guidelines insights: non-small cell lung cancer, version 5.2018 publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2018.0062 – ident: 2025072923350935000_10.5.e003956.144 doi: 10.1016/j.jtho.2018.08.2035 – volume: 376 start-page: 191 year: 2017 ident: 2025072923350935000_10.5.e003956.146 article-title: Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab publication-title: N Engl J Med doi: 10.1056/NEJMc1614298 – ident: 2025072923350935000_10.5.e003956.127 doi: 10.1038/s41591-020-01224-2 – ident: 2025072923350935000_10.5.e003956.191 doi: 10.1186/s40425-018-0382-2 – ident: 2025072923350935000_10.5.e003956.166 doi: 10.1634/theoncologist.2012-0279 – ident: 2025072923350935000_10.5.e003956.35 doi: 10.17226/13058 – ident: 2025072923350935000_10.5.e003956.2 doi: 10.3322/caac.21708 – volume: 182 start-page: 459 year: 1995 ident: 2025072923350935000_10.5.e003956.22 article-title: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation publication-title: J Exp Med doi: 10.1084/jem.182.2.459 – ident: 2025072923350935000_10.5.e003956.75 doi: 10.1200/JCO.20.01605 – ident: 2025072923350935000_10.5.e003956.3 – ident: 2025072923350935000_10.5.e003956.135 doi: 10.1200/JCO.19.00189 – ident: 2025072923350935000_10.5.e003956.106 doi: 10.1093/neuonc/now235 – ident: 2025072923350935000_10.5.e003956.65 doi: 10.1158/1538-7445.AM2020-CT221 – volume: 60 start-page: 234 year: 2005 ident: 2025072923350935000_10.5.e003956.170 article-title: Effect of lung cancer surgery on quality of life publication-title: Thorax doi: 10.1136/thx.2004.031872 – volume: 66 start-page: 214 year: 2017 ident: 2025072923350935000_10.5.e003956.112 article-title: Malignant Mesothelioma Mortality - United States, 1999-2015 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm6608a3 – ident: 2025072923350935000_10.5.e003956.175 doi: 10.1016/s1470-2045(17)30690-3 – ident: 2025072923350935000_10.5.e003956.12 doi: 10.1016/S1470-2045(20)30641-0 – volume: 18 start-page: 274 year: 2017 ident: 2025072923350935000_10.5.e003956.168 article-title: Evolution of symptom burden of advanced lung cancer over a decade publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2016.12.010 – volume: 126 start-page: 1550 year: 2020 ident: 2025072923350935000_10.5.e003956.188 article-title: Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): a toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs publication-title: Cancer doi: 10.1002/cncr.32692 – ident: 2025072923350935000_10.5.e003956.43 doi: 10.1158/1078-0432.CCR-19-0624 – ident: 2025072923350935000_10.5.e003956.54 doi: 10.1093/annonc/mdz167 – ident: 2025072923350935000_10.5.e003956.140 doi: 10.1200/JCO.2017.77.6385 – ident: 2025072923350935000_10.5.e003956.7 doi: 10.1016/S0140-6736(15)01281-7 – ident: 2025072923350935000_10.5.e003956.62 doi: 10.1200/JCO.21.00174 – ident: 2025072923350935000_10.5.e003956.118 doi: 10.1007/s00262-008-0642-y – volume: 2 start-page: e192535- year: 2019 ident: 2025072923350935000_10.5.e003956.36 article-title: Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2019.2535 – ident: 2025072923350935000_10.5.e003956.110 doi: 10.1016/S0140-6736(20)32714-8 – volume: 39 year: 2021 ident: 2025072923350935000_10.5.e003956.71 article-title: Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2021.39.15_suppl.9001 – ident: 2025072923350935000_10.5.e003956.119 doi: 10.1073/pnas.0712237105 – ident: 2025072923350935000_10.5.e003956.56 doi: 10.1038/s41416-020-01099-7 – ident: 2025072923350935000_10.5.e003956.66 doi: 10.1634/theoncologist.2015-0498 – volume: 5 start-page: 557 year: 2008 ident: 2025072923350935000_10.5.e003956.134 article-title: CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS publication-title: Nat Clin Pract Oncol doi: 10.1038/ncponc1183 – ident: 2025072923350935000_10.5.e003956.95 doi: 10.1200/JCO.20.02212 – ident: 2025072923350935000_10.5.e003956.52 doi: 10.1371/journal.pone.0229179 – ident: 2025072923350935000_10.5.e003956.40 – ident: 2025072923350935000_10.5.e003956.47 doi: 10.1093/annonc/mdy275 – volume: 27 start-page: 1910 year: 2021 ident: 2025072923350935000_10.5.e003956.126 article-title: Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial publication-title: Nat Med doi: 10.1038/s41591-021-01541-0 – ident: 2025072923350935000_10.5.e003956.33 doi: 10.1158/2159-8290.CD-17-0593 – volume: 14 start-page: S214 year: 2019 ident: 2025072923350935000_10.5.e003956.150 article-title: OA04.02 CheckMate 817: first-line nivolumab + ipilimumab in patients with ECoG PS 2 and other special populations with advanced NSCLC publication-title: Journal of Thoracic Oncology doi: 10.1016/j.jtho.2019.08.424 – volume: 2017 start-page: 1 year: 2017 ident: 2025072923350935000_10.5.e003956.49 article-title: Landscape of microsatellite instability across 39 cancer types publication-title: JCO Precis Oncol doi: 10.1200/PO.17.00073 – ident: 2025072923350935000_10.5.e003956.101 doi: 10.1016/j.jss.2015.01.043 – volume: 18 start-page: 497 year: 2017 ident: 2025072923350935000_10.5.e003956.173 article-title: Emotional problems, quality of life, and symptom burden in patients with lung cancer publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2017.02.008 – volume: 29A Suppl 1 start-page: S51 year: 1993 ident: 2025072923350935000_10.5.e003956.184 article-title: Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS) publication-title: Eur J Cancer doi: 10.1016/S0959-8049(05)80262-X – ident: 2025072923350935000_10.5.e003956.111 – ident: 2025072923350935000_10.5.e003956.48 doi: 10.6004/jnccn.2018.0062 – ident: 2025072923350935000_10.5.e003956.121 doi: 10.1158/1078-0432.CCR-09-1624 – volume: 31 start-page: 798 year: 2020 ident: 2025072923350935000_10.5.e003956.87 article-title: Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the Pacific trial publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.03.287 – volume: 18 start-page: 637 year: 2014 ident: 2025072923350935000_10.5.e003956.163 article-title: Chemotherapy education for patients with cancer: a literature review publication-title: Clin J Oncol Nurs doi: 10.1188/14.CJON.637-640 – ident: 2025072923350935000_10.5.e003956.96 doi: 10.1016/j.jtho.2019.12.109 – ident: 2025072923350935000_10.5.e003956.79 – ident: 2025072923350935000_10.5.e003956.141 doi: 10.1038/s41591-020-01224-2 – ident: 2025072923350935000_10.5.e003956.145 doi: 10.1016/j.jtho.2018.11.016 – ident: 2025072923350935000_10.5.e003956.8 doi: 10.1016/S0140-6736(18)32409-7 – volume: 83 start-page: 93 year: 2023 ident: 2025072923350935000_10.5.e003956.32 article-title: Tremelimumab: First Approval publication-title: Drugs (Abingdon Engl) – volume: 124 start-page: 383 year: 2021 ident: 2025072923350935000_10.5.e003956.63 article-title: A phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer publication-title: Br J Cancer doi: 10.1038/s41416-020-01099-7 – ident: 2025072923350935000_10.5.e003956.159 doi: 10.1016/j.cllc.2017.02.008 – ident: 2025072923350935000_10.5.e003956.133 doi: 10.1186/s40425-019-0585-1 – ident: 2025072923350935000_10.5.e003956.139 doi: 10.6004/jnccn.2018.0047 – ident: 2025072923350935000_10.5.e003956.180 doi: 10.1634/theoncologist.2012-0279 – volume: 3 start-page: 1051 year: 2017 ident: 2025072923350935000_10.5.e003956.46 article-title: A prospective, multi-institutional, Pathologist-Based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.0013 – ident: 2025072923350935000_10.5.e003956.155 – ident: 2025072923350935000_10.5.e003956.31 doi: 10.1007/s12253-018-0469-6 – volume: 38 year: 2020 ident: 2025072923350935000_10.5.e003956.104 article-title: Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (Ce) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2020.38.15_suppl.9000 – ident: 2025072923350935000_10.5.e003956.183 doi: 10.1200/JCO.1993.11.3.570 – ident: 2025072923350935000_10.5.e003956.193 doi: 10.1056/NEJMoa1809064 – ident: 2025072923350935000_10.5.e003956.161 doi: 10.2147/OTT.S100685 – ident: 2025072923350935000_10.5.e003956.72 doi: 10.1158/1538-7445.AM2020-CT221 – ident: 2025072923350935000_10.5.e003956.16 doi: 10.1016/j.immuni.2013.07.012 – ident: 2025072923350935000_10.5.e003956.138 doi: 10.1136/jitc-2021-002435 – ident: 2025072923350935000_10.5.e003956.117 doi: 10.1016/j.ctrv.2017.07.002 – volume: 18 start-page: 663 year: 2017 ident: 2025072923350935000_10.5.e003956.98 article-title: Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30230-9 – ident: 2025072923350935000_10.5.e003956.29 – ident: 2025072923350935000_10.5.e003956.80 doi: 10.1158/1538-7445.AM2021-CT003 – ident: 2025072923350935000_10.5.e003956.4 doi: 10.1016/j.jtho.2019.10.002 – ident: 2025072923350935000_10.5.e003956.185 doi: 10.1016/0169-5002(95)00450-F – ident: 2025072923350935000_10.5.e003956.91 doi: 10.1200/JCO.20.00793 – ident: 2025072923350935000_10.5.e003956.45 doi: 10.1016/j.annonc.2021.09.016 – ident: 2025072923350935000_10.5.e003956.125 doi: 10.1016/j.jtho.2018.04.034 – ident: 2025072923350935000_10.5.e003956.190 doi: 10.1016/j.cllc.2018.05.011 – ident: 2025072923350935000_10.5.e003956.69 doi: 10.1016/j.jtho.2020.06.015 – ident: 2025072923350935000_10.5.e003956.137 doi: 10.1186/s40425-017-0300-z – ident: 2025072923350935000_10.5.e003956.30 – ident: 2025072923350935000_10.5.e003956.93 doi: 10.1016/S1470-2045(16)30098-5 – volume: 20 start-page: e470 year: 2019 ident: 2025072923350935000_10.5.e003956.97 article-title: Relationship between prior radiotherapy and Checkpoint-Inhibitor pneumonitis in patients with advanced non-small-cell lung cancer publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2019.02.018 – ident: 2025072923350935000_10.5.e003956.24 doi: 10.1200/JCO.2020.38.15_suppl.9501 – volume: 21 start-page: e169 year: 2020 ident: 2025072923350935000_10.5.e003956.160 article-title: Lower survival in patients who develop pneumonitis following immunotherapy for lung cancer publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2019.10.009 – ident: 2025072923350935000_10.5.e003956.27 doi: 10.1136/jitc-2019-000398 – ident: 2025072923350935000_10.5.e003956.124 doi: 10.1158/1078-0432.CCR-13-0895 – volume: 34 start-page: 3025 year: 2016 ident: 2025072923350935000_10.5.e003956.53 article-title: Pd-L1 expression in advanced NSCLC: primary lesions versus metastatic sites and impact of sample age publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2016.34.15_suppl.3025 – volume: 38 start-page: 2369 year: 2020 ident: 2025072923350935000_10.5.e003956.103 article-title: Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study publication-title: J Clin Oncol doi: 10.1200/JCO.20.00793 – volume: 45 start-page: 228 year: 2009 ident: 2025072923350935000_10.5.e003956.128 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – ident: 2025072923350935000_10.5.e003956.116 doi: 10.1200/JCO.2015.61.6870 |
| SSID | ssj0001033888 |
| Score | 2.3568392 |
| Snippet | Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of... |
| SourceID | doaj pubmedcentral proquest pubmed crossref bmj |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e003956 |
| SubjectTerms | Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy Clinical medicine Clinical practice guidelines clinical trials as topic guidelines as topic Humans Immunotherapy Immunotherapy - adverse effects Lung cancer lung neoplasms Lung Neoplasms - drug therapy Mesothelioma Mesothelioma - therapy Mesothelioma, Malignant Patients Position and Guidelines Position article and guidelines Quality of Life Small Cell Lung Carcinoma - etiology Small Cell Lung Carcinoma - therapy |
| SummonAdditionalLinks | – databaseName: BMJ Open Access Journals dbid: 9YT link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEBZtCiGX0nedpkWFFpqDs7YlS_YxWRqSQnrpBtKT0TPdsGuXze4hPyH_OjPyI3UpoezFrDVjyzNjzVgz3xDyiWlYVYX1sfCFjbkvdVyalMVep4n1EG8kDquRz76Lk3P-7SK_6AJFrIW5mq_NgV5eteUMCNBUI6L8JJ84LCPNxQF-ln5MniAOF6bwlT9n999UEgi4iqLfjWQisANFyCBkDtQ7ZJvlAmKa0EUGrjNajgJq_79czb8zJv9Ygo6fkaed70gPW2E_J49c_YJsn3W74y_JbZeCScERpadY-NGVV93QxtMpyndFv_w4nU33aV8RSfsyKXq5QcQrYESbms5H1MgPjumQlY78FvCaoKZlqmpLl-4aCRbzZqlekfPjr7PpSdy1Woh1nsl1rL1wwqbOaZVl1hkrTabL0orUC5UrMPxCM6GcLzDA89aXjAnpZKI4l86n7DXZqpvavSWUy4B5prnPEu6VKZRnXJs8N4kG76yMyGd47lVnKtdViEKYqFBUFYqqakUVkUkvmcp0eOXYNmPxAMX-QPG7xep4YOwRCnsYhyjb4Y9mdVl1RlspmfDUe6k1xG3GKQUTLblyEMHb1LAsInu9qtzPJ8P2LdiVHmb6cTgNRos7Map2zSaMAU8WfnlE3rSaNdxJr58RkSOdG93q-Ew9_xWAwcsU0S3l7n8-4XdkJ8NijpC-uUe21quNew8u1lp_CHZ1B3ufIxc priority: 102 providerName: BMJ Publishing Group Ltd – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagB8QFlfIKLchIINFDtE7s2MkRVlQtUrnQSr1FfsJWuwlqdw_9Cf3XzDgPNqgqF5RLFD9ke2bsmXjmG0LecwOnqnQhlaF0qQiVSSub8TSYjLkA9gbzGI18-k0en4uvF8XFVqov9Anr4IG7hZtpxUQWgjIGdGfrtQ6gswjtwYpymeVx92UV2zKm4t8VBqZXWQ73klzOLhdrCyyRg_HMeIX5qh-a1eXkNIqg_Xdpmn87TG6dQEe75EmvOtJP3ZCfkge-2SOPTvvL8WfktvfApKCH0hOM--ijq25oG-gcyXtFP34_OZsf0iEgkg5RUvTHBgGvoCPaNnQxaY39wTsdndKxvyXsEtR2nerG0ZW_xgbLRbvSz8n50Zez-XHaZ1pITZGrdWqC9NJl3hud585bp2xuqsrJLEhdaJD70nCpfSjRvgsuVJxL5RXTQigPFHlBdpq28a8IFSpCnhkRciaCtqUOXBhbFJYZUM6qhHyAda97SbmuoxHCZY30qZE-dUefhMwGytS2hyvHrBnLe1ocji1-dVAd99T9jMQe6yHIdvwArFf3rFf_i_UScjCwyp_55Ji9BZPSw0zfjcUgs3gRoxvfbmIdUGThKRLysuOscSS8kGBy5yohasJzk6FOS5rFz4gLXmUIbqle_4-57ZPHOQZ6RNfOA7Kzvtr4N6B-rc3bKGm_AerbL3c priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LbtQw0KJFQlwQb1IKMhJI9BBtEjt2ckKwomqRyoVW2lvkZ9lqNyn7OPQT-GtmEidLEFrlEsUey87M2DOeFyHvmYZTVVgfC1_YmPtSx6VJWex1mlgP-kbiMBr54rs4u-LfZvksXLitg1tlvye2G7VtDN6RTzKsioHFvstPt79irBqF1tVQQuOA3E9BEsHSDXImd3csCShgRdFbJ5mY3Mw3BggjAxU6YSVWrT7Qy5vRmdSm7v-fvPmv2-Rf59DpY_IoCJD0c4fxJ-Seq5-SBxfBRP6M_A5-mBSkUXqO0R8hxuqONp5OEckr-vHH-eX0hPZhkbSPlaLXW0x7BQPRpqbzETSOB-90cE3H8RawV1DTDapqS5dujQCLebNUz8nV6dfL6Vkc6i3EOs_kJtZeOGFT57TKMuuMlSbTZWlF6oXKFXB_oZlQzheo5XnrS8aEdDJRnEvnU_aCHNZN7V4RymWb-ExznyXcK1Moz7g2eW4SDSJaGZEP8N-rwC_rqlVFmKgQPxXip-rwE5FJj5nKhKTlWDtjsQfiZIC47RJ27On7BZE99MNU2-2HZnVdBc6tlEx46r3UGpQ345SChZZcOVDjbWpYFpHjnlR269lRa0TeDc3AuWiOUbVrtm0fEGfhySPysqOsYSYsF6B4ZzIickRzo6mOW-r5zzY7eJliikt5tH9ar8nDDAM5WtfNY3K4WW3dGxCvNvpty0N_AM3TJks priority: 102 providerName: ProQuest |
| Title | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma |
| URI | https://jitc.bmj.com/content/10/5/e003956.full https://www.ncbi.nlm.nih.gov/pubmed/35640927 https://www.proquest.com/docview/2674832029 https://www.proquest.com/docview/2672323235 https://pubmed.ncbi.nlm.nih.gov/PMC9157337 https://doaj.org/article/a7041ff7bb174ceaaf1394ae132d1c32 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZrC6UvY-su9dYFDTZYH7zali3ZD2O0oaUdpIwtGdmT0bVLSewtTWD9CfvXO5LltB6hD8NgG1tHSDpH1vmsc0HoDRGwqlJlQmpyFaamEGEhYxIaEUfKAN6ItPVGHlzQs1H6aZyNb92j_QBer4V2Np_UaD59__vXzUeY8B98RpLDq8lCArcTwMURAX1_A2253SJryOeVfffHJQI4luftXuUawh20TTIKiMflmBGzq85i5WL6r1NE_7WnvLNAnT5CD71miY8aUXiMHuhqF20P_N75E_THG2hiUFPxuXUL8c5XN7g2uG-5P8fvvp4P-we49ZfErRMVvlzaeFhQEa4rPOlQ2_rgHq9s1m19U_iIYNlUyiuFZ_raEkwn9Yw_RaPTk2H_LPSJGEKRJWwRCkM1VbHWgieJ0lIxmYiiUDQ2lGccPgu5IJRrk1v4Z5QpCKFMs4inKdMmJs_QZlVXeg_hlLmIaCI1SZQaLnNuSCpklslIgO5WBOgtjHvZykHpMAqhpWVVaVlVNqwK0GHLmVL6aOY2qcb0HoqDFcXPJpLHPWWPLbNX5WwMbvegnl-WfkqXnEVpbAwTAlCd1JxDR4uUa8D3KpYkCdB-Kyq3_Ulschebsx56-nr1Gqa03afhla6XrgzouXBkAXreSNaqJa18Boh1ZK7T1O6bavLDhQ0vYhv7kr34b8qXaCexzh_O3HMfbS7mS_0KVLKF6KENNmZwLr4Pe2jrqD8YfIPr8cnF5y8995uj5-biX8KWPRQ |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe2TgJeEN8EBhiJSewhamInTvIwIVY2tWytEHTS3jJ_jk5tMvohtD-Bf4q_DV_itBShvk15iRL75OTO5zv77n4IvaPCrqpMGZ-ZVPmRyYSfyZD6RoSBMtbfCDRkI_cHrHsWfT6Pz7fQ7yYXBsIqG51YKWpVStgjbxNAxQCw7-zD9Q8fUKPgdLWB0OAOWkEdVCXGXGLHib75aV242UHvk-X3HiHHR8NO13coA76ISTL3hWGaqVBrwQlRWqpEEpFlioWG8ZhbmU8FZVybFHwbo0xGKUt0EvAoSrQJqaW7jXYi2EBpoZ3Do8GXr6tdnsC6gGnanI9S1r4azaUVTWKd-IBmgJu9LSZXa6tiBR7wP4v338DNv1bC4wfovjNh8cda5h6iLV08Qnf67pD-MfrlIkGxtYdxD_JPXJbXDS4N7oCYTfH7b71hZx83iZm4ydbClwsovGUJ4bLAo7XeQM_e42VwPNAbW22FZU2UFwpP9Aw6jEflhD9BZ7fCi6eoVZSFfo5wlFSl10RkSBAZLlNuaCRkHMtAWCMx89Ce_e-5m7GzvHKGKMuBPznwJ6_546F2w5lcurLpgN4x3tBjf9njui4ZsqHtITB72Q6KfVcPyull7nRHzpMgCo1JhLDuo9Sc2w_NIq5DSlQoKfHQbiMqq-9ZzRcPvV2-troDDoR4octF1cYa1PaKPfSslqzlSGjMrOtPEg8lazK3NtT1N8Xoe1WfPAuhyGbyYvOw3qC73WH_ND_tDU5eonsE0kqqQNJd1JpPF_qVNfbm4rWbURhd3PYk_gMtEmuT |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF71IVVcEJSXocAiUYkerNi79q59qBBNGzWURhW0Um9mnyVVYpc8hPoT-Gv8KmadddIglFuVixXvjtaex854Z-ZD6D2VsKsybUNmMx0mNpdhrmIaWhlH2kK8ERlXjXzaY8cXyefL9HIN_WlqYVxaZWMTa0OtK-W-kbeIQ8VwYN95y_q0iLPDzsebn6FDkHInrQ2chvAwC3q_bjfmizxOzO0vCOfG-91D4P0uIZ2j8_Zx6BEHQpkSPgmlZYbp2BgpCNFGaa6IzHPNYstEKkD-M0mZMDZzcY7VNqeUccMjkSTc2JgC3XW0yWHXh0Bw8-Cod_Z18cUngnAwy5qzUspa1_2JAjElENBHNHcY2utyeL20Q9ZAAv_zfv9N4ryzK3YeoYfencWfZvL3GK2ZchttnfoD-yfot88KxeAb466rRfEVX7e4srjtRG6EP3zrnrf3cFOkiZvKLXw1dU24gBCuStxfmu3owTWeJ8o7egOwXFjNiIpS46EZuwmDfjUUT9HFvfDiGdooq9K8QDjhdRs2mVgSJVaoTFiaSJWmKpLgMOYB2oX3XnjtHRd1YERZ4fhTOP4UM_4EqNVwplC-hbpD8hismLE3n3Ezax-yYuyBY_Z8nGv8Xf9Rja4Kb0cKwaMktpZLCaGkMkLAg-aJMDElOlaUBGinEZXF8yx0J0Dv5rfBjrjDIVGaalqPAecafmmAns8ka74SmrIkygkPEF-SuaWlLt8p-z_qXuV57Bpu8perl_UWbYEyF1-6vZNX6AFxFSZ1TukO2piMpuY1-H0T-cYrFEbf71uH_wIunW_X |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Society+for+Immunotherapy+of+Cancer+%28SITC%29+clinical+practice+guideline+on+immunotherapy+for+the+treatment+of+lung+cancer+and+mesothelioma&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Govindan%2C+Ramaswamy&rft.au=Aggarwal%2C+Charu&rft.au=Antonia%2C+Scott+J&rft.au=Davies%2C+Marianne&rft.date=2022-05-01&rft.pub=BMJ+Publishing+Group&rft.eissn=2051-1426&rft.volume=10&rft.issue=5&rft_id=info:doi/10.1136%2Fjitc-2021-003956&rft_id=info%3Apmid%2F35640927&rft.externalDocID=PMC9157337 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2051-1426&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2051-1426&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2051-1426&client=summon |